{"protocolSection":{"identificationModule":{"nctId":"NCT02747927","orgStudyIdInfo":{"id":"DEN-301"},"secondaryIdInfos":[{"id":"U1111-1166-8401","type":"REGISTRY","domain":"WHO"},{"id":"PHRR150522-001010","type":"REGISTRY","domain":"PHRR"},{"id":"2018-003979-34","type":"REGISTRY","domain":"EudraCT"},{"id":"2018","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2018"}],"organization":{"fullName":"Takeda","class":"INDUSTRY"},"briefTitle":"Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children","officialTitle":"Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old","acronym":"TIDES"},"statusModule":{"statusVerifiedDate":"2025-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-04-26","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-07-11","type":"ACTUAL"},"completionDateStruct":{"date":"2024-06-28","type":"ACTUAL"},"studyFirstSubmitDate":"2016-04-14","studyFirstSubmitQcDate":"2016-04-19","studyFirstPostDateStruct":{"date":"2016-04-22","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-07-23","resultsFirstSubmitQcDate":"2021-07-23","resultsFirstPostDateStruct":{"date":"2021-08-18","type":"ACTUAL"},"dispFirstSubmitDate":"2019-07-25","dispFirstSubmitQcDate":"2019-07-25","dispFirstPostDateStruct":{"date":"2019-08-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-11-06","lastUpdatePostDateStruct":{"date":"2025-11-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Takeda","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The main purpose of this study is to evaluate the efficacy of 2 doses of Tetravalent Dengue Vaccine Candidate (TDV) in preventing symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in 4 to 16 year old participants.","detailedDescription":"The vaccine being tested in this study is Takeda's Tetravalent Dengue Vaccine Candidate (TDV). TDV is being tested to protect people against dengue fever and to look at long-term safety results. This study will look at the success rate of TDV in preventing dengue fever (vaccine efficacy) and long-term side effects of the vaccine.\n\nThe study will be conducted in 5 parts. Part 1 will evaluate vaccine efficacy (VE) and will last a minimum of 15 months. Part 2 will be for an additional 6 months to evaluate VE. Part 3 will evaluate long-term safety by following participants for side effects and will last an additional 3 years. Part 4 will evaluate safety for 13 months post-booster vaccination. Part 5 will be the long-term safety follow-up for 1 year after completion of Part 4. Participants may be enrolled into a dry-run to commence and test febrile surveillance methodology; this dry-run part may be up to 10 months prior to receiving study injection, however, will not be applicable to all trials sites or participants.\n\nApproximately 20,100 participants will be enrolled into the study and randomly assigned (by chance) to one of the two treatment groups-which will remain undisclosed to the participants and study doctors during the study (unless there is an urgent medical need):\n\n* TDV 0.5 mL subcutaneous injection\n* Placebo (dummy inactive subcutaneous injection) - this is a solution that looks like the study drug but has no active ingredient\n\nAll participants will receive a single injection of TDV or placebo on Day 1, Day 90. Participation in a booster phase will be offered to approximately 10,500 participants to receive (TDV or placebo) on Day 1b (Day 1 in booster phase). A subset of participants will be asked to record any local symptoms at the injection site (Pain, Erythema and Swelling) in a diary card for 7 days after each injection. The same subset of participants will also be asked to record any systemic symptoms (child \\<6 years: fever, irritability/fussiness, drowsiness, loss of appetite and child ≥6 years: fever, headache, asthenia, malaise and myalgia) in a diary card for 14 days after each injection.\n\nThis multi-center trial will be conducted worldwide. The overall time to participate in this study is approximately 7 years excluding the dry-run. Participants will make multiple visits to the clinic and will be contacted at least every week for the entire study duration."},"conditionsModule":{"conditions":["Healthy Volunteers"],"keywords":["Drug therapy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":20099,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received placebo-matching TDV, 0.5 milliliters (mL), subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1 booster \\[b\\] (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study.","interventionNames":["Drug: Placebo"]},{"label":"Tetravalent Dengue Vaccine (TDV) 0.5 mL","type":"EXPERIMENTAL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study.","interventionNames":["Biological: Tetravalent Dengue Vaccine (TDV)"]}],"interventions":[{"type":"DRUG","name":"Placebo","description":"TDV placebo-matching SC injection.","armGroupLabels":["Placebo"]},{"type":"BIOLOGICAL","name":"Tetravalent Dengue Vaccine (TDV)","description":"TDV SC injection.","armGroupLabels":["Tetravalent Dengue Vaccine (TDV) 0.5 mL"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Vaccine Efficacy (VE) of Two Doses of Tetravalent Dengue Vaccine Candidate (TDV) in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype","description":"The VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR). The primary endpoint of VE was assessed using the number of virologically-confirmed dengue fever cases that occurred during Part 1.","timeFrame":"30 days post-second vaccination (Day 120 [Month 4]) until the end of Part 1 (Month 15) when at least 120 cases of dengue fever were confirmed and minimum duration of participant follow-up was 12 months post-second vaccination"}],"secondaryOutcomes":[{"measure":"VE of Two Doses of TDV in Preventing Hospitalization Due to Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases requiring hospitalization due to virologically-confirmed dengue fever that occurred during Part 1 and Part 2.","timeFrame":"From 30 days post-second vaccination (Day 120 [Month 4]) until the end of Part 2 (Month 21)"},{"measure":"VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Each Dengue Serotype","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases that occurred during Part 1 and Part 2.","timeFrame":"From 30 days post-second vaccination (Day 120 [Month 4]) until the end of Part 2 (Month 21)"},{"measure":"VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype in Participants Dengue Seronegative at Baseline","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases that occurred during Part 1 and Part 2.","timeFrame":"From 30 days post-second vaccination (Day 120 [Month 4]) until the end of Part 2 (Month 21)"},{"measure":"VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype in Participants Dengue Seropositive at Baseline","description":"VE is defined as 1 - (λv/λC), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases that occurred during Part 1 and Part 2.","timeFrame":"From 30 days post-second vaccination (Day 120 [Month 4]) until the end of Part 2 (Month 21)"},{"measure":"VE of Two Doses of TDV in Preventing Virologically-Confirmed Severe Dengue Fever Induced by Any Dengue Serotype","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. Severe cases were determined by Adjudication Committee. VE was assessed using the number of severe cases due to virologically-confirmed dengue fever that occurred during Part 1 and Part 2.","timeFrame":"From 30 days post-second vaccination (Day 120 [Month 4]) until the end of Part 2 (Month 21)"},{"measure":"Percentage of Participants With Solicited Local Injection Site Adverse Events (AEs) by Severity in the Safety Set Immunogenicity Subset","description":"Solicited local AEs at injection site are defined as pain, erythema and swelling that occurred within 7 days after each vaccination. The participant/legal guardian recorded the severity of each AE (except erythema and swelling) according to the diary card instruction as none, mild, moderate, or severe. Severity grades for erythema and swelling were derived from the recorded diameters. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation.","timeFrame":"Days 1 through 7 after each vaccination"},{"measure":"Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity in the Safety Set Immunogenicity Subset","description":"Solicited systemic AEs in children (\\< 6 years) are defined as fever, irritability/fussiness, drowsiness and loss of appetite that occurred within 14 days after each vaccination. Solicited systemic AEs in children (≥ 6 years) are defined as fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination. The participant/legal guardian recorded the severity of each AE (except fever) according to the diary card instruction as none, mild, moderate, or severe. Severity grades for fever were derived from the recorded body temperature measurements and presented using the proposed temperature increments published by the Brighton Collaboration. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation.","timeFrame":"Days 1 through 14 after each vaccination on Day 1 (Month 0) and Day 90 (Month 3)"},{"measure":"Percentage of Participants With Any Unsolicited Adverse Events (AEs) in the Safety Set Immunogenicity Subset","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study. Percentages were rounded off to the nearest single decimal place.","timeFrame":"Days 1 through 28 after each vaccination on Day 1 (Month 0) and Day 90 (Month 3)"},{"measure":"Percentage of Participants With Serious Adverse Events (SAEs) During Parts 1 and 2","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. Percentages were rounded off to the nearest single decimal place. In the category 'Part 1 and 2 combined' participants are counted only once even if they experienced events in both Part 1 and Part 2 in order to yield total of unique participants who had SAEs.","timeFrame":"From Day 1 until the end of Parts 1 (Month 15) and 2 (Month 21)"},{"measure":"Percentage of Participants With Fatal SAEs and SAEs Related to Study Drug During the First and Second Half of Part 3","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation.","timeFrame":"First and Second half (18 months each) of Part 3 (up to 3 years, beginning at Month 22)"},{"measure":"Seropositivity Rate for Each of the Four Dengue Serotypes in the Immunogenicity Subset","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The four DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation.","timeFrame":"Pre-vaccination on Day 1 (Baseline), post-first vaccination on Month 1, pre-vaccination on Month 3; post-second vaccination at Months 4, 9 and 15, and then annually (up to 3 years)"},{"measure":"Seropositivity Rate for Multiple Dengue Serotypes in the Immunogenicity Subset","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for any one (monovalent), two (bivalent), three (trivalent), and four (tetravalent) dengue serotypes, as well as at least bivalent (seropositive for ≥2 dengue serotypes) and at least trivalent (seropositive for ≥3 dengue serotypes), is derived from the titers of dengue-neutralizing antibodies. Seropositive response is defined as a reciprocal neutralizing titer ≥ 10. The four DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation.","timeFrame":"Pre-vaccination on Day 1 (Baseline), post-first vaccination on Month 1, pre-vaccination on Month 3; post-second vaccination at Months 4, 9 and 15, and then annually (up to 3 years)"},{"measure":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the Four Dengue Serotypes in the Immunogenicity Subset","description":"GMTs of neutralizing antibodies were measured via microneutralization test 50% (MNT50). The four DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.","timeFrame":"Pre-vaccination on Day 1 (Baseline), post-first vaccination on Month 1, pre-vaccination on Month 3; post-second vaccination at Months 4, 9 and 15, and then annually (up to 3 years)"}],"otherOutcomes":[{"measure":"VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases due to virologically-confirmed dengue fever that occurred during the first half of Part 3.","timeFrame":"First half of Part 3 (18 months beginning at Month 22)"},{"measure":"VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases due to virologically-confirmed dengue fever that occurred during the second half of Part 3.","timeFrame":"Second half of Part 3 (18 months beginning at Month 40)"},{"measure":"VE of Two Doses of TDV in Preventing Hospitalization Due to Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases requiring hospitalization due to virologically-confirmed dengue fever that occurred during the first half of Part 3.","timeFrame":"First half of Part 3 (18 months beginning at Month 22)"},{"measure":"VE of Two Doses of TDV in Preventing Hospitalization Due to Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases requiring hospitalization due to virologically-confirmed dengue fever that occurred during the second half of Part 3.","timeFrame":"Second half of Part 3 (18 months beginning at Month 40)"},{"measure":"VE of a TDV Booster Dose in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype From 30 Days Post-Booster Vaccination (Day 30 Booster [b] (Month 1b)) Until the End of Part 4","description":"The VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases.","timeFrame":"From 30 days post-booster vaccination (Day 30 booster [b] (Month 1b)) until the end of Part 4 (Month 13b)"},{"measure":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Each Dengue Serotype From 30 Days Post-Booster Vaccination (Day 30b [Month 1b]) Until the End of Part 4","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases.","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 4 (Month 13b)"},{"measure":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Any And Each Dengue Serotype in Dengue Seronegative Participants at Baseline From 30 Days Post-Booster Vaccination (Day 30b [Month 1b]) Until the End of Part 4","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted only once for the \"Any Dengue Serotype\" category but counted separately for each dengue serotype they belong to.","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 4 (Month 13b)"},{"measure":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Any and Each Dengue Serotype in Dengue Seropositive Participants at Baseline From 30 Days Post-Booster Vaccination (Day 30b [Month 1b]) Until the End of Part 4","description":"VE is defined as 1 - (λv/λC), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted only once for the \"Any Dengue Serotype\" category but counted separately for each dengue serotype they belong to.","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 4 (Month 13b)"},{"measure":"VE of a TDV Booster Dose in Preventing Hospitalization Due to Virologically Confirmed Dengue Fever Induced by Any Dengue Serotype From 30 Days Post-Booster Vaccination (Day 30b [Month 1b]) Until the End of Part 4","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases requiring hospitalization due to virologically-confirmed dengue fever.","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 4 (Month 13b)"},{"measure":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Severe Dengue Fever Induced by Any Dengue Serotype From 30 Days Post-Booster Vaccination (Day 30b [Month 1b]) Until the End of Part 4","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. Severe cases were determined by Adjudication Committee. VE was assessed using the number of severe cases due to virologically-confirmed dengue fever.","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 4 (Month 13b)"},{"measure":"VE of a TDV Booster Dose in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype During Part 5","description":"The VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted only once for the any dengue serotype.","timeFrame":"From Month 14b until the end of Part 5 (Month 25b)"},{"measure":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Each Dengue Serotype During Part 5","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted separately for each dengue serotype.","timeFrame":"From Month 14b until the end of Part 5 (Month 25b)"},{"measure":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Any And Each Dengue Serotype in Dengue Seronegative Participants at Baseline During Part 5","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted only once for the \"Any Dengue Serotype\" category but counted separately for each dengue serotype they belong to.","timeFrame":"From Month 14b until the end of Part 5 (Month 25b)"},{"measure":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Any and Each Dengue Serotype in Dengue Seropositive Participants at Baseline During Part 5","description":"VE is defined as 1 - (λv/λC), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted only once for the \"Any Dengue Serotype\" category but counted separately for each dengue serotype they belong to.","timeFrame":"From Month 14b until the end of Part 5 (Month 25b)"},{"measure":"VE of a TDV Booster Dose in Preventing Hospitalization Due to Virologically Confirmed Dengue Fever Induced by Any Dengue Serotype During Part 5","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases requiring hospitalization due to virologically-confirmed dengue fever.","timeFrame":"From Month 14b until the end of Part 5 (Month 25b)"},{"measure":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Severe Dengue Fever Induced by Any Dengue Serotype During Part 5","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. Severe cases were determined by Adjudication Committee. VE was assessed using the number of severe cases due to virologically-confirmed dengue fever.","timeFrame":"From Month 14b until the end of Part 5 (Month 25b)"},{"measure":"VE of a TDV Booster Dose in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype for Parts 4 And 5 Combined","description":"The VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases.","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b) until the end of Part 5 (Month 25b)"},{"measure":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Each Dengue Serotype for Parts 4 And 5 Combined","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases.","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 5 (Month 25b)"},{"measure":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Any And Each Dengue Serotype in Dengue Seronegative Participants at Baseline for Parts 4 And 5 Combined","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted only once for the \"Any Dengue Serotype\" category but counted separately for each dengue serotype they belong to.","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 5 (Month 25b)"},{"measure":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Any and Each Dengue Serotype in Dengue Seropositive Participants at Baseline for Parts 4 And 5 Combined","description":"VE is defined as 1 - (λv/λC), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted only once for the \"Any Dengue Serotype\" category but counted separately for each dengue serotype they belong to.","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 5 (Month 25b)"},{"measure":"VE of a TDV Booster Dose in Preventing Hospitalization Due to Virologically Confirmed Dengue Fever Induced by Any Dengue Serotype for Parts 4 And 5 Combined","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases requiring hospitalization due to virologically-confirmed dengue fever.","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 5 (Month 25b)"},{"measure":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Severe Dengue Fever Induced by Any Dengue Serotype for Parts 4 And 5 Combined","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. Severe cases were determined by Adjudication Committee. VE was assessed using the number of severe cases due to virologically-confirmed dengue fever.","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 5 (Month 25b)"},{"measure":"Percentage of Participants With Solicited Local Injection Site Adverse Events (AEs) by Severity in the Safety Set-Booster-Immunogenicity Subset During Part 4","description":"Solicited local AEs at injection site are defined as pain, erythema and swelling that occurred within 7 days after each vaccination. The participant/legal guardian recorded the severity of each AE (except erythema and swelling) according to the diary card instruction as none, mild, moderate, or severe. Severity grades for erythema and swelling were derived from the recorded diameters. Percentages were rounded off to the nearest single decimal place.","timeFrame":"Days 1b through 7b after booster vaccination in Part 4"},{"measure":"Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity in the Safety Set-Booster-Immunogenicity Subset During Part 4","description":"Solicited systemic AEs are defined as fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination. The participant/legal guardian recorded the severity of each AE (except fever) according to the diary card instruction as none, mild, moderate, or severe. Severity grades for fever were derived from the recorded body temperature measurements and presented using the proposed temperature increments published by the Brighton Collaboration. Percentages were rounded off to the nearest single decimal place except the data point where rounding-up may lead to data misinterpretation.","timeFrame":"Days 1b through 14b after booster vaccination in Part 4"},{"measure":"Percentage of Participants With Any Unsolicited Adverse Events (AEs) in the Safety Set-Booster-Immunogenicity Subset During Part 4","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study. Percentages were rounded off to the nearest single decimal place.","timeFrame":"Days 1b through 28b after booster vaccination in Part 4"},{"measure":"Percentage of Participants With Serious Adverse Events (SAEs) During Parts 4 and 5","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. Percentages were rounded off to the nearest single decimal place. In the category 'Part 4 and 5 combined' participants are counted only once even if they experienced events in both Part 4 and Part 5 in order to yield total of unique participants who had SAEs.","timeFrame":"From Day 1b until the end of Part 4 (Month 13b) and Part 5 (Month 25b)"},{"measure":"Percentage of Participants With Fatal SAEs and SAEs Related to Study Drug During Parts 4 and 5","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation. In the category 'Part 4 and 5 combined' participants are counted only once even if they experienced events in both Part 4 and Part 5 in order to yield total of unique participants who had SAEs.","timeFrame":"From Day 1b until the end of Part 4 (Month 13b) and Part 5 (Month 25b)"},{"measure":"Seropositivity Rate for Each of The 4 Dengue Serotypes During Parts 4 and 5","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The four DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation.","timeFrame":"Pre-booster Vaccination on Day 1b (Month 0b) and post-booster vaccination on Day 30b (Month 1b), Day 180b (Month 6b), Day 395b (Month 13b) and Day 760b (Month 25b) in Parts 4 and 5"},{"measure":"Seropositivity Rate for Multiple Dengue Serotypes During Parts 4 and 5","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for any one (monovalent), two (bivalent), three (trivalent), and four (tetravalent) dengue serotypes, as well as at least bivalent (seropositive for ≥2 dengue serotypes) and at least trivalent (seropositive for ≥3 dengue serotypes), is derived from the titers of dengue-neutralizing antibodies. Seropositive response is defined as a reciprocal neutralizing titer ≥ 10. The four DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation.","timeFrame":"Pre-booster vaccination on Day 1b (Month 0b) and post-booster vaccination on Day 30b (Month 1b), Day 180b (Month 6b), Day 395b (Month 13b) and Day 760b (Month 25b) in Parts 4 and 5"},{"measure":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the Four Dengue Serotypes During Parts 4 And 5","description":"GMTs of neutralizing antibodies were measured via MNT50. The four DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.","timeFrame":"Pre-booster Vaccination on Day 1b (Month 0b) and post-booster vaccination on Day 30b (Month 1b), Day 180b (Month 6b), Day 395b (Month 13b) and Day 760b (Month 25b) in Parts 4 and 5"},{"measure":"Geometric Mean Ratio (GMR) of Neutralizing Antibodies for Each Dengue Serotype","description":"The GMR is the geometric mean of the ratio of the two visits being compared.","timeFrame":"Pre-booster Vaccination on Day 1b (Month 0b) versus post-booster vaccination on Day 30b (Month 1b) in Part 4"},{"measure":"GMR of Neutralizing Antibodies for Each Dengue Serotype","description":"The GMR is the geometric mean of the ratio of the two visits being compared.","timeFrame":"Pre-booster Vaccination on Day 1b (Month 0b) versus post-booster vaccination on Day 180b (Month 6b) in Part 4"},{"measure":"GMR of Neutralizing Antibodies for Each Dengue Serotype","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared.","timeFrame":"Pre-booster Vaccination on Day 1b (Month 0b) versus post-booster vaccination on Day 395b (Month 13b) in Part 4"},{"measure":"GMR of Neutralizing Antibodies for Each Dengue Serotype","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared.","timeFrame":"Pre-booster Vaccination on Day 1b (Month 0b) versus post-booster vaccination on Day 720b (Month 25b) in Part 5"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Is aged 4 to 16 years, inclusive, at the time of randomization.\n2. Is in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the Investigator.\n3. The participant and/or the participant's parent/guardian signs and dates an assent/written informed consent form where applicable, and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local regulatory requirements.\n4. Can comply with trial procedures and are available for the duration of follow-up.\n\nInclusion criteria for Booster Phase:\n\n1. Is included in the per-protocol set (PPS) of the trial.\n2. Was aged 4 to 11 years at the time of randomization in the study (Day 1 \\[Month 0\\]).\n\nExclusion Criteria:\n\n1. Has febrile illness (temperature ≥38°C) or moderate or severe acute illness or infection at the time of randomization.\n2. Has history of or any illness that, in the opinion of the Investigator, might interfere with the results of the trial or pose an additional risk to the participant due to participation in the trial.\n3. Has received any other vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to Day 1 (Month 0) or planning to receive any vaccine within 28 days after Day 1 (Month 0).\n4. Has participated in any clinical trial with another investigational product 30 days prior to Day 1 (Month 0) or intent to participate in another clinical trial at any time during the conduct of this trial.\n5. Has previously participated in any clinical trial of a dengue candidate vaccine, or previous receipt of a dengue vaccine.\n6. Is first degree relative of individuals involved in trial conduct.\n7. Females of childbearing potential who are sexually active, and who have not used any of the acceptable contraceptive methods for at least 2 months prior to Day 1 (Month 0).\n8. Females of childbearing potential who are sexually active, and who refuse to use an acceptable contraceptive method up to 6 weeks post-second vaccination.\n9. Deprived of freedom by administrative or court order, or in an emergency setting, or hospitalized involuntarily.\n10. Current alcohol abuse or drug addiction that may interfere with the participant's ability to comply with trial procedures.\n11. Identified as an employee of the Investigator or trial center, with direct involvement in the proposed trial or other trials under the direction of that Investigator or trial center.\n\nExclusion criteria for Booster Phase:\n\n1. Receipt of any other vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to Day 1b (Month 0b), or planning to receive any vaccine within 28 days after Day 1b (Month 0b).\n2. Participation in any clinical trial with another investigational product at any time during participation in this trial or intent to participate in another clinical trial at any time during the conduct of the booster phase of this trial.","healthyVolunteers":true,"sex":"ALL","minimumAge":"4 Years","maximumAge":"16 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Takeda","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Universidade Federal Do Espirito Santo Hospital Universitario Cassiano Antonio de Moraes HUCAM","city":"Vitória","state":"Espírito Santo","zip":"29040-091","country":"Brazil","geoPoint":{"lat":-20.31944,"lon":-40.33778}},{"facility":"Associacao Obras Sociais Irma Dulce Hospital Santo Antonio","city":"Salvador","state":"Estado de Bahia","zip":"40415-000","country":"Brazil","geoPoint":{"lat":-12.97563,"lon":-38.49096}},{"facility":"Universidade Federal de Mato Grosso do Sul","city":"Campo Grande","state":"Mato Grosso do Sul","zip":"79070-900","country":"Brazil","geoPoint":{"lat":-20.44278,"lon":-54.64639}},{"facility":"Centro de Estudos e Pesquisa em Molestias Infecciosas LTDA (CPCLIN)","city":"Cidade Alta","state":"Natal - RN","zip":"59025-050","country":"Brazil","geoPoint":{"lat":-22.8156,"lon":-43.29236}},{"facility":"Centro de Atencion e Investigacion Medica S.A - CAIMED - Aguazul - PPDS-PV","city":"Aguazul","state":"Casanare Department","country":"Colombia","geoPoint":{"lat":5.17282,"lon":-72.54706}},{"facility":"Centro de Atencion e Investigacion Medica S.A - CAIMED - Yopal - PPDS-PV","city":"Yopal","state":"Casanare Department","country":"Colombia","geoPoint":{"lat":5.33573,"lon":-72.3939}},{"facility":"Centro de Atencion e Investigacion Medica S.A. - CAIMED - Acacias - PPDS-PV","city":"Acacías","state":"Meta Department","zip":"507001","country":"Colombia","geoPoint":{"lat":3.98695,"lon":-73.75797}},{"facility":"Centro de Estudios em Infectologia Pediatrica SAS (CEIP S.A.S)","city":"Cali","state":"San Fernando","country":"Colombia","geoPoint":{"lat":3.43054,"lon":-76.5199}},{"facility":"Hospital Maternidad Nuestra Senora de Altagracia","city":"Santo Domingo","state":"Distrito Nacional Santo Domingo","zip":"10204","country":"Dominican Republic","geoPoint":{"lat":18.47186,"lon":-69.89232}},{"facility":"Calle Alexander Fleming No. 90 Esquina 37, Ensanche La Fe","city":"Santo Domingo","state":"Distrito Nacional Santo Domingo","zip":"10514","country":"Dominican Republic","geoPoint":{"lat":18.47186,"lon":-69.89232}},{"facility":"Universidad Nacional Autonoma de Nicaragua","city":"León","country":"Nicaragua","geoPoint":{"lat":12.43527,"lon":-86.87862}},{"facility":"Centro De Vacunacion Internacional, S.A. (Cevaxin)","city":"Panama City","zip":"10662","country":"Panama","geoPoint":{"lat":8.9936,"lon":-79.51973}},{"facility":"Centro De Vacunacion Internacional, S.A. (Cevaxin) Sede 24 de Diciembre","city":"Panama City","country":"Panama","geoPoint":{"lat":8.9936,"lon":-79.51973}},{"facility":"Centro De Vacunacion Internacional, S.A. (Cevaxin) Sede Plaza Carolina","city":"Panama City","country":"Panama","geoPoint":{"lat":8.9936,"lon":-79.51973}},{"facility":"Centro De Vacunacion Internacional, S.A.(Cevaxin) - La Chorrera","city":"Panama City","country":"Panama","geoPoint":{"lat":8.9936,"lon":-79.51973}},{"facility":"Dela Salle Health Sciences Institute","city":"Dasmariñas","state":"Cavite","zip":"4114","country":"Philippines","geoPoint":{"lat":14.32944,"lon":120.93667}},{"facility":"Philippines-AFRIMS Virology Research Unit","city":"Cebu City","state":"Cebu","zip":"6000","country":"Philippines","geoPoint":{"lat":10.31672,"lon":123.89071}},{"facility":"Research Institute for Tropical Medicine","city":"City of Muntinlupa","zip":"1781","country":"Philippines","geoPoint":{"lat":14.39028,"lon":121.0475}},{"facility":"University of the Philippine Manila","city":"Ermita","zip":"1000","country":"Philippines","geoPoint":{"lat":10.9,"lon":122.71667}},{"facility":"Las Pinas Health Center A","city":"Las Piñas","country":"Philippines","geoPoint":{"lat":14.45056,"lon":120.98278}},{"facility":"Las Pinas Health Center D","city":"Las Piñas","country":"Philippines","geoPoint":{"lat":14.45056,"lon":120.98278}},{"facility":"Lady Ridgeway Hospital for Children","city":"Colombo","zip":"00800","country":"Sri Lanka","geoPoint":{"lat":6.93548,"lon":79.84868}},{"facility":"Colombo South Teaching Hospital","city":"Dehiwala","zip":"10250","country":"Sri Lanka","geoPoint":{"lat":6.85626,"lon":79.86159}},{"facility":"Negombo General Hospital","city":"Negombo","zip":"11500","country":"Sri Lanka","geoPoint":{"lat":7.2083,"lon":79.8358}},{"facility":"Colombo North Teaching Hospital","city":"Ragama","zip":"11010","country":"Sri Lanka","geoPoint":{"lat":7.0292,"lon":79.917}},{"facility":"The Hospital for Tropical Diseases","city":"Bangkok","state":"Bangkok","zip":"10270","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Phramongkutklao Hospital","city":"Bangkok","state":"Bangkok","zip":"10400","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Srinagarind Hospital","city":"Khon Kaen","zip":"40002","country":"Thailand","geoPoint":{"lat":16.44671,"lon":102.833}}]},"referencesModule":{"references":[{"pmid":"42480195","type":"DERIVED","citation":"Gottardo R, Dean H, Nascimento EJM, Tricou V, Sharma M. Beyond neutralization: A comprehensive framework for evaluating humoral immunity induced by a live-attenuated tetravalent dengue vaccine. Vaccine. 2026 Aug 13;88:128929. doi: 10.1016/j.vaccine.2026.128929. Epub 2026 Jul 21."},{"pmid":"40120920","type":"DERIVED","citation":"Pfaar H, Lopez-Medina E, Escudero I, Hutagalung Y, Roubinis N, Thakrar S, Corazon Borja-Tabora CF, Tricou V, Tuboi S. Operational challenges and lessons learned from conducting febrile surveillance in a long-term randomized dengue vaccine trial in Latin America and Asia-Pacific. Travel Med Infect Dis. 2025 May-Jun;65:102840. doi: 10.1016/j.tmaid.2025.102840. Epub 2025 Mar 20."},{"pmid":"40099800","type":"DERIVED","citation":"Rauscher M, Youard Z, Faccin A, Patel SS, Pang H, Zent O. Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine. Expert Rev Vaccines. 2025 Dec;24(1):221-229. doi: 10.1080/14760584.2025.2480297. Epub 2025 Mar 27."},{"pmid":"39173075","type":"DERIVED","citation":"Fernando L, Kastner R, Wickramasinghe P, Fernando AD, Gunasekera D, Nguyen VH, Liu M, LeFevre I, Wallace D, Folschweiller N, Biswal S. Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience. PLoS Negl Trop Dis. 2024 Aug 22;18(8):e0012376. doi: 10.1371/journal.pntd.0012376. eCollection 2024 Aug."},{"pmid":"38995684","type":"DERIVED","citation":"Borja-Tabora C, Fernando L, Lopez Medina E, Reynales H, Rivera L, Saez-Llorens X, Sirivichayakul C, Yu D, Folschweiller N, Moss KJ, Rauscher M, Tricou V, Zhao Y, Biswal S. Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group. Clin Infect Dis. 2025 Feb 5;80(1):199-206. doi: 10.1093/cid/ciae369."},{"pmid":"38682569","type":"DERIVED","citation":"Sirivichayakul C, Biswal S, Saez-Llorens X, Lopez-Medina E, Borja-Tabora C, Bravo L, Kosalaraksa P, Alera MT, Reynales H, Rivera L, Watanaveeradej V, Yu D, Espinoza F, Dietze R, Fernando L, Wickramasinghe VP, Moreira ED Jr, Fernando AD, Gunasekera D, Luz K, Venancio da Cunha R, Oliveira AL, Rauscher M, Fan H, Borkowski A, Escudero I, Tuboi S, Lloyd E, Tricou V, Folschweiller N, LeFevre I, Vargas LM, Wallace D; TIDES Study Group. Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination. J Infect Dis. 2024 Dec 16;230(6):e1214-e1225. doi: 10.1093/infdis/jiae222."},{"pmid":"38245116","type":"DERIVED","citation":"Tricou V, Yu D, Reynales H, Biswal S, Saez-Llorens X, Sirivichayakul C, Lopez P, Borja-Tabora C, Bravo L, Kosalaraksa P, Vargas LM, Alera MT, Rivera L, Watanaveeradej V, Dietze R, Fernando L, Wickramasinghe VP, Moreira ED Jr, Fernando AD, Gunasekera D, Luz K, Oliveira AL, Tuboi S, Escudero I, Hutagalung Y, Lloyd E, Rauscher M, Zent O, Folschweiller N, LeFevre I, Espinoza F, Wallace D. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 2024 Feb;12(2):e257-e270. doi: 10.1016/S2214-109X(23)00522-3."},{"pmid":"36878213","type":"DERIVED","citation":"Saez-Llorens X, Biswal S, Borja-Tabora C, Fernando L, Liu M, Wallace D, Folschweiller N, Reynales H, LeFevre I; TIDES Study Group. Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue. Am J Trop Med Hyg. 2023 Mar 6;108(4):722-726. doi: 10.4269/ajtmh.22-0673. Print 2023 Apr 5."},{"pmid":"34606595","type":"DERIVED","citation":"Rivera L, Biswal S, Saez-Llorens X, Reynales H, Lopez-Medina E, Borja-Tabora C, Bravo L, Sirivichayakul C, Kosalaraksa P, Martinez Vargas L, Yu D, Watanaveeradej V, Espinoza F, Dietze R, Fernando L, Wickramasinghe P, Duarte MoreiraJr E, Fernando AD, Gunasekera D, Luz K, Venancioda Cunha R, Rauscher M, Zent O, Liu M, Hoffman E, LeFevre I, Tricou V, Wallace D, Alera M, Borkowski A. Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003). Clin Infect Dis. 2022 Aug 24;75(1):107-117. doi: 10.1093/cid/ciab864."},{"pmid":"32197105","type":"DERIVED","citation":"Biswal S, Borja-Tabora C, Martinez Vargas L, Velasquez H, Theresa Alera M, Sierra V, Johana Rodriguez-Arenales E, Yu D, Wickramasinghe VP, Duarte Moreira E Jr, Fernando AD, Gunasekera D, Kosalaraksa P, Espinoza F, Lopez-Medina E, Bravo L, Tuboi S, Hutagalung Y, Garbes P, Escudero I, Rauscher M, Bizjajeva S, LeFevre I, Borkowski A, Saez-Llorens X, Wallace D; TIDES study group. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. Lancet. 2020 May 2;395(10234):1423-1433. doi: 10.1016/S0140-6736(20)30414-1. Epub 2020 Mar 17."},{"pmid":"31693803","type":"DERIVED","citation":"Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, Sirivichayakul C, Watanaveeradej V, Rivera L, Espinoza F, Fernando L, Dietze R, Luz K, Venancio da Cunha R, Jimeno J, Lopez-Medina E, Borkowski A, Brose M, Rauscher M, LeFevre I, Bizjajeva S, Bravo L, Wallace D; TIDES Study Group. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. N Engl J Med. 2019 Nov 21;381(21):2009-2019. doi: 10.1056/NEJMoa1903869. Epub 2019 Nov 6."}],"seeAlsoLinks":[{"label":"To obtain more information about this study, click this link.","url":"https://clinicaltrials.takeda.com/study-detail/5f6b60224db2bf003ab49693?idFilter=%5B%22DEN-301%22%5D"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR"],"accessCriteria":"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.","url":"https://vivli.org/ourmember/takeda/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Healthy children and adolescents were randomized in a 2:1 ratio to receive either tetravalent dengue vaccine (TDV) or placebo followed by a booster vaccination.","recruitmentDetails":"Participants took part in the study at various investigative sites globally from 26 April 2016 to 28 June 2024.","groups":[{"id":"FG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 milliliter (mL), subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"FG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"periods":[{"title":"Part 1: Vaccine Efficacy (Months 0-15)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"6698"},{"groupId":"FG001","numSubjects":"13401"}]},{"type":"Safety Set","comment":"Safety Set included all randomized participants who received at least 1 dose of the trial vaccines (TDV or placebo).","achievements":[{"groupId":"FG000","numSubjects":"6687"},{"groupId":"FG001","numSubjects":"13380"}]},{"type":"Treatment Misallocations","comment":"These are participants who received the wrong study vaccination, i.e. instead of Placebo/Placebo or TDV/TDV for first and second vaccination, they received a mix of TDV and Placebo. These participants are not included in the Placebo or TDV arm of the Safety Set and were separately analyzed for selected summary tables only.","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"COMPLETED","comment":"Number of participants who had not discontinued from the trial at the end of Part 1.","achievements":[{"groupId":"FG000","numSubjects":"6520"},{"groupId":"FG001","numSubjects":"13035"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"178"},{"groupId":"FG001","numSubjects":"366"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"14"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"26"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"42"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Withdrawal by Participant and/or Participants Parent/Guardian","reasons":[{"groupId":"FG000","numSubjects":"131"},{"groupId":"FG001","numSubjects":"260"}]},{"type":"Without Adult Consent in Place","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Reason not Specified","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"15"}]}]},{"title":"Part 2: Additional VE (Months 16-21)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"6520"},{"groupId":"FG001","numSubjects":"13035"}]},{"type":"COMPLETED","comment":"Number of participants who had not discontinued from the trial at the end of Part 2.","achievements":[{"groupId":"FG000","numSubjects":"6488"},{"groupId":"FG001","numSubjects":"12963"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"72"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"17"}]},{"type":"Withdrawal by Participant&/ortheir Parent/Guardian","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"33"}]},{"type":"Without Adult Consent in Place","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Reason Not Specified","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"6"}]}]},{"title":"Part 3: Long Term Safety & VE (3 Years)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"6488"},{"groupId":"FG001","numSubjects":"12963"}]},{"type":"COMPLETED","comment":"Number of participants who had not discontinued from the trial at the end of Part 3.","achievements":[{"groupId":"FG000","numSubjects":"6080"},{"groupId":"FG001","numSubjects":"12179"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"408"},{"groupId":"FG001","numSubjects":"784"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"67"},{"groupId":"FG001","numSubjects":"149"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"120"},{"groupId":"FG001","numSubjects":"228"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal by Participant and/or Participants Parent/Guardian","reasons":[{"groupId":"FG000","numSubjects":"119"},{"groupId":"FG001","numSubjects":"227"}]},{"type":"Without Adult Consent in Place","reasons":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"150"}]},{"type":"Reason Not Specified","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"18"}]}]},{"title":"Part 4: Booster VE & Safety (13 Months)","milestones":[{"type":"STARTED","comment":"Only participants from the PPS who were 4 to 11 years of age at the time of randomization in the trial on Day 1 (Month 0) can participate in the booster phase of this trial.","achievements":[{"groupId":"FG000","numSubjects":"2986"},{"groupId":"FG001","numSubjects":"5991"}]},{"type":"Safety Set - Booster","comment":"Safety Set - Booster (SS-B) included all participants who received the booster dose of the trial vaccine (TDV or placebo).","achievements":[{"groupId":"FG000","numSubjects":"2985"},{"groupId":"FG001","numSubjects":"5990"}]},{"type":"Treatment-Misallocations","comment":"These are participants who received the wrong study vaccination during the booster. These participants are not included in the Placebo or the TDV arm of the Safety Set and were separately analyzed for selected summary tables only.","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"COMPLETED","comment":"Number of participants who had not discontinued from the trial at the end of Part 4.","achievements":[{"groupId":"FG000","numSubjects":"2940"},{"groupId":"FG001","numSubjects":"5890"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"101"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"13"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"Withdrawal by Participant and/or Participants Parent/Guardian","reasons":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"60"}]},{"type":"Without Adult Consent in Place","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Reason Not Specified","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"9"}]}]},{"title":"Part 5: Booster VE & Safety (1 Year)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"2940"},{"groupId":"FG001","numSubjects":"5890"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2842"},{"groupId":"FG001","numSubjects":"5672"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"98"},{"groupId":"FG001","numSubjects":"218"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"30"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"27"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"40"}]},{"type":"Without Adult Consent in Place","reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"29"}]},{"type":"Reason Not Specified","reasons":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"89"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Per-Protocol Set (PPS) included all participants in the Full Analysis Set (FAS) who had no major protocol violations. FAS included all randomized participants who received at least 1 dose of the trial vaccines.","groups":[{"id":"BG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"BG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"9.6","spread":"3.34"},{"groupId":"BG001","value":"9.6","spread":"3.35"},{"groupId":"BG002","value":"9.6","spread":"3.35"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"3098"},{"groupId":"BG001","value":"6314"},{"groupId":"BG002","value":"9412"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"3219"},{"groupId":"BG001","value":"6390"},{"groupId":"BG002","value":"9609"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"American Indian or Alaska Native","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"2379"},{"groupId":"BG001","value":"4821"},{"groupId":"BG002","value":"7200"}]}]},{"title":"Asian","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"2934"},{"groupId":"BG001","value":"5888"},{"groupId":"BG002","value":"8822"}]}]},{"title":"Black or African American","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"708"},{"groupId":"BG001","value":"1353"},{"groupId":"BG002","value":"2061"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]},{"title":"White","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"131"},{"groupId":"BG001","value":"284"},{"groupId":"BG002","value":"415"}]}]},{"title":"More than one race or Unknown","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"164"},{"groupId":"BG001","value":"356"},{"groupId":"BG002","value":"520"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Brazil","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"504"},{"groupId":"BG001","value":"1091"},{"groupId":"BG002","value":"1595"}]}]},{"title":"Colombia","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"1155"},{"groupId":"BG001","value":"2268"},{"groupId":"BG002","value":"3423"}]}]},{"title":"Dominican Republic","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"533"},{"groupId":"BG001","value":"1007"},{"groupId":"BG002","value":"1540"}]}]},{"title":"Nicaragua","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"239"},{"groupId":"BG001","value":"512"},{"groupId":"BG002","value":"751"}]}]},{"title":"Panama","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"944"},{"groupId":"BG001","value":"1930"},{"groupId":"BG002","value":"2874"}]}]},{"title":"Philippines","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"1306"},{"groupId":"BG001","value":"2554"},{"groupId":"BG002","value":"3860"}]}]},{"title":"Sri Lanka","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"683"},{"groupId":"BG001","value":"1368"},{"groupId":"BG002","value":"2051"}]}]},{"title":"Thailand","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12704"},{"groupId":"BG002","value":"19021"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"953"},{"groupId":"BG001","value":"1974"},{"groupId":"BG002","value":"2927"}]}]}]},{"title":"Height","populationDescription":"Number analyzed is number of participants with data available for height at Baseline.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"cm","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6313"},{"groupId":"BG001","value":"12696"},{"groupId":"BG002","value":"19009"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"134.87","spread":"18.976"},{"groupId":"BG001","value":"134.84","spread":"19.151"},{"groupId":"BG002","value":"134.85","spread":"19.092"}]}]}]},{"title":"Weight","populationDescription":"Number analyzed is number of participants with data available for weight at Baseline.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6317"},{"groupId":"BG001","value":"12697"},{"groupId":"BG002","value":"19014"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"33.77","spread":"14.506"},{"groupId":"BG001","value":"33.98","spread":"14.951"},{"groupId":"BG002","value":"33.91","spread":"14.805"}]}]}]},{"title":"Body Mass Index (BMI)","description":"BMI=weight (kg)/\\[height (m)\\^2\\].","populationDescription":"Number analyzed is number of participants with data available for BMI at Baseline.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6313"},{"groupId":"BG001","value":"12689"},{"groupId":"BG002","value":"19002"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"17.67","spread":"3.645"},{"groupId":"BG001","value":"17.76","spread":"3.831"},{"groupId":"BG002","value":"17.73","spread":"3.770"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Vaccine Efficacy (VE) of Two Doses of Tetravalent Dengue Vaccine Candidate (TDV) in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype","description":"The VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR). The primary endpoint of VE was assessed using the number of virologically-confirmed dengue fever cases that occurred during Part 1.","populationDescription":"PPS included all participants in the FAS who had no major protocol violations. FAS included all randomized participants who received at least 1 dose of the trial vaccines. Overall number of participants analyzed is the number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"30 days post-second vaccination (Day 120 [Month 4]) until the end of Part 1 (Month 15) when at least 120 cases of dengue fever were confirmed and minimum duration of participant follow-up was 12 months post-second vaccination","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6316"},{"groupId":"OG001","value":"12700"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"61"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Assuming true VE of 60% and, virologically confirmed cases of dengue fever induced by any dengue serotype occurring from 30 days post 2nd vaccination (Day 120) until end of Part 1 would provide at least 90% power to rule out vaccine effect of ≤25%.","nonInferiorityType":"OTHER","pValue":"<0.001","pValueComment":"Statistical significance was concluded if the lower bound of the 95% CI for the VE was above 25%. Since the hypotheses was tested in a confirmatory manner at a 2-sided significance level of 5%, the calculated p-value was compared with 0.025.","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"80.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"73.3","ciUpperLimit":"85.3","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"SECONDARY","title":"VE of Two Doses of TDV in Preventing Hospitalization Due to Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases requiring hospitalization due to virologically-confirmed dengue fever that occurred during Part 1 and Part 2.","populationDescription":"PPS included all participants in the FAS who had no major protocol violations. FAS included all randomized participants who received at least 1 dose of the trial vaccines. Overall number of participants analyzed is the number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-second vaccination (Day 120 [Month 4]) until the end of Part 2 (Month 21)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6316"},{"groupId":"OG001","value":"12700"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"13"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.001","pValueComment":"Statistical significance was concluded if the lower bound of the 95% CI for the VE was above 0%. Since the hypotheses was tested in a confirmatory manner at a 2-sided significance level of 5%, the calculated p-value was compared with 0.025.","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"90.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"82.6","ciUpperLimit":"94.7","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"SECONDARY","title":"VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Each Dengue Serotype","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases that occurred during Part 1 and Part 2.","populationDescription":"PPS included all participants in the FAS who had no major protocol violations. FAS included all randomized participants who received at least 1 dose of the trial vaccines. Overall number of participants analyzed is the number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-second vaccination (Day 120 [Month 4]) until the end of Part 2 (Month 21)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6316"},{"groupId":"OG001","value":"12700"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"38"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"8"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"63"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"DENV-1","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"69.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"54.8","ciUpperLimit":"79.9","estimateComment":"VE and two-sided 95% CIs are estimated from a Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-2","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"95.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"89.9","ciUpperLimit":"97.6","estimateComment":"VE and two-sided 95% CIs are estimated from a Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-3","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"48.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"27.1","ciUpperLimit":"64.1","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-4","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"50.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-69.7","ciUpperLimit":"85.8","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"SECONDARY","title":"VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype in Participants Dengue Seronegative at Baseline","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases that occurred during Part 1 and Part 2.","populationDescription":"PPS included all participants in the FAS who had no major protocol violations. FAS included all randomized participants who received at least 1 dose of the trial vaccines. Overall number of participants analyzed is the number of participants with seronegative baseline status and with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-second vaccination (Day 120 [Month 4]) until the end of Part 2 (Month 21)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1726"},{"groupId":"OG001","value":"3531"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"39"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"66.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"49.1","ciUpperLimit":"77.5","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"SECONDARY","title":"VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype in Participants Dengue Seropositive at Baseline","description":"VE is defined as 1 - (λv/λC), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases that occurred during Part 1 and Part 2.","populationDescription":"PPS included all participants in the FAS who had no major protocol violations. FAS included all randomized participants who received at least 1 dose of the trial vaccines. Overall number of participants analyzed is the number of participants with seropositive baseline status and with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-second vaccination (Day 120 [Month 4]) until the end of Part 2 (Month 21)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4589"},{"groupId":"OG001","value":"9167"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"75"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"76.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"68.5","ciUpperLimit":"81.9","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"SECONDARY","title":"VE of Two Doses of TDV in Preventing Virologically-Confirmed Severe Dengue Fever Induced by Any Dengue Serotype","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. Severe cases were determined by Adjudication Committee. VE was assessed using the number of severe cases due to virologically-confirmed dengue fever that occurred during Part 1 and Part 2.","populationDescription":"PPS included all participants in the FAS who had no major protocol violations. FAS included all randomized participants who received at least 1 dose of the trial vaccines. Overall number of participants analyzed is the number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-second vaccination (Day 120 [Month 4]) until the end of Part 2 (Month 21)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6316"},{"groupId":"OG001","value":"12700"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"2.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-978.5","ciUpperLimit":"91.1","estimateComment":"VE and two-sided 95% CIs are estimated from a Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"SECONDARY","title":"Percentage of Participants With Solicited Local Injection Site Adverse Events (AEs) by Severity in the Safety Set Immunogenicity Subset","description":"Solicited local AEs at injection site are defined as pain, erythema and swelling that occurred within 7 days after each vaccination. The participant/legal guardian recorded the severity of each AE (except erythema and swelling) according to the diary card instruction as none, mild, moderate, or severe. Severity grades for erythema and swelling were derived from the recorded diameters. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation.","populationDescription":"The Safety Set (SS)- Immunogenicity Subset included all randomized participants in the safety/immunogenicity subset who received at least 1 dose of the trial vaccines (TDV or placebo). Number analyzed is the number of participants with data available for analyses for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 1 through 7 after each vaccination","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1329"},{"groupId":"OG001","value":"2663"}]}],"classes":[{"title":"Children of Age <6 Years; After First Vaccination; Pain: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"327"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.5"},{"groupId":"OG001","value":"21.1"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"327"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"},{"groupId":"OG001","value":"2.1"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"327"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.3"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Erythema; Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"324"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.6"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Erythema; Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"324"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.6"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Erythema; Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"324"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Swelling; Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"324"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"1.9"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Swelling; Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"324"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.9"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Swelling; Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"324"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Pain: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"324"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.3"},{"groupId":"OG001","value":"18.2"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"324"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"},{"groupId":"OG001","value":"2.5"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"324"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Erythema; Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"322"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.6"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Erythema; Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"322"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Erythema; Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"322"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Swelling; Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"323"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.9"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Swelling; Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"323"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.6"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Swelling; Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"323"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Pain: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1143"},{"groupId":"OG001","value":"2284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.9"},{"groupId":"OG001","value":"23.4"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1143"},{"groupId":"OG001","value":"2284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.2"},{"groupId":"OG001","value":"3.9"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1143"},{"groupId":"OG001","value":"2284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3"},{"groupId":"OG001","value":"0.7"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Erythema; Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1140"},{"groupId":"OG001","value":"2276"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1.0"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Erythema; Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1140"},{"groupId":"OG001","value":"2276"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Erythema; Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1140"},{"groupId":"OG001","value":"2276"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Swelling; Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1140"},{"groupId":"OG001","value":"2272"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"1.2"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Swelling; Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1140"},{"groupId":"OG001","value":"2272"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Swelling; Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1140"},{"groupId":"OG001","value":"2272"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination Pain; Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1116"},{"groupId":"OG001","value":"2251"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.7"},{"groupId":"OG001","value":"19.7"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination Pain; Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1116"},{"groupId":"OG001","value":"2251"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"},{"groupId":"OG001","value":"3.2"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination Pain; Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1116"},{"groupId":"OG001","value":"2251"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3"},{"groupId":"OG001","value":"0.6"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination Erythema; Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1113"},{"groupId":"OG001","value":"2248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0898"},{"groupId":"OG001","value":"0.9"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination Erythema; Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1113"},{"groupId":"OG001","value":"2248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination Erythema; Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1113"},{"groupId":"OG001","value":"2248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination Swelling; Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1112"},{"groupId":"OG001","value":"2246"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0899"},{"groupId":"OG001","value":"0.6"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination Swelling; Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1112"},{"groupId":"OG001","value":"2246"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination Swelling; Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1112"},{"groupId":"OG001","value":"2246"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity in the Safety Set Immunogenicity Subset","description":"Solicited systemic AEs in children (\\< 6 years) are defined as fever, irritability/fussiness, drowsiness and loss of appetite that occurred within 14 days after each vaccination. Solicited systemic AEs in children (≥ 6 years) are defined as fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination. The participant/legal guardian recorded the severity of each AE (except fever) according to the diary card instruction as none, mild, moderate, or severe. Severity grades for fever were derived from the recorded body temperature measurements and presented using the proposed temperature increments published by the Brighton Collaboration. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation.","populationDescription":"The SS- Immunogenicity Subset included all randomized participants in the safety/immunogenicity subset who received at least 1 dose of the trial vaccines (TDV or placebo). Number analyzed is the number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 1 through 14 after each vaccination on Day 1 (Month 0) and Day 90 (Month 3)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1329"},{"groupId":"OG001","value":"2663"}]}],"classes":[{"title":"Children of Age <6 Years; After First Vaccination; Irritability/Fussiness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"325"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.3"},{"groupId":"OG001","value":"7.7"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Irritability/Fussiness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"325"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.9"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Irritability/Fussiness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"325"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.3"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Drowsiness; Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"325"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.1"},{"groupId":"OG001","value":"8.3"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Drowsiness; Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"325"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2.2"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Drowsiness; Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"325"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.6"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Loss of Appetite; Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"325"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.1"},{"groupId":"OG001","value":"12.3"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Loss of Appetite; Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"325"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"},{"groupId":"OG001","value":"1.2"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Loss of Appetite; Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"325"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.6"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Fever; 38.0-<38.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"311"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.3"},{"groupId":"OG001","value":"3.9"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Fever; 38.5-<39.0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"311"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"1.9"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Fever; 39.0-<39.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"311"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"1.9"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Fever; 39.5-<40.0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"311"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7"},{"groupId":"OG001","value":"1.0"}]}]},{"title":"Children of Age <6 Years; After First Vaccination; Fever: >=40.0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"311"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Irritability/Fussiness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1"},{"groupId":"OG001","value":"5.3"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Irritability/Fussiness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.4"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Irritability/Fussiness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.4"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Drowsiness; Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.9"},{"groupId":"OG001","value":"6.0"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Drowsiness; Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1.1"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Drowsiness; Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Loss of Appetite; Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.9"},{"groupId":"OG001","value":"6.0"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Loss of Appetite; Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7"},{"groupId":"OG001","value":"1.1"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Loss of Appetite; Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7"},{"groupId":"OG001","value":"0.4"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Fever: 38.0-<38.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"313"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.4"},{"groupId":"OG001","value":"1.3"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Fever: 38.5-<39.0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"313"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"},{"groupId":"OG001","value":"3.5"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Fever: 39.0-<39.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"313"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"},{"groupId":"OG001","value":"1.3"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Fever: 39.5-<40.0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"313"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.6"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Fever: 40.0-<40.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"313"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.3"}]}]},{"title":"Children of Age <6 Years; After Second Vaccination; Fever: >=40.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"313"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Headache: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1142"},{"groupId":"OG001","value":"2284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.8"},{"groupId":"OG001","value":"17.5"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Headache: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1142"},{"groupId":"OG001","value":"2284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4"},{"groupId":"OG001","value":"5.3"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Headache: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1142"},{"groupId":"OG001","value":"2284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7"},{"groupId":"OG001","value":"1.8"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Asthenia: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1142"},{"groupId":"OG001","value":"2285"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.8"},{"groupId":"OG001","value":"8.8"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Asthenia: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1142"},{"groupId":"OG001","value":"2285"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.8"},{"groupId":"OG001","value":"2.8"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Asthenia: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1142"},{"groupId":"OG001","value":"2285"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0.8"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Malaise: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1142"},{"groupId":"OG001","value":"2283"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"11.8"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Malaise: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1142"},{"groupId":"OG001","value":"2283"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3"},{"groupId":"OG001","value":"3.4"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Malaise: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1142"},{"groupId":"OG001","value":"2283"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"},{"groupId":"OG001","value":"1.0"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Muscle Pain: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1142"},{"groupId":"OG001","value":"2283"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.8"},{"groupId":"OG001","value":"14.1"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Muscle Pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1142"},{"groupId":"OG001","value":"2283"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"2.9"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Muscle Pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1142"},{"groupId":"OG001","value":"2283"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.9"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Fever: 38.0-<38.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1052"},{"groupId":"OG001","value":"2088"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.0"},{"groupId":"OG001","value":"3.0"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Fever: 38.5-<39.0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1052"},{"groupId":"OG001","value":"2088"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"},{"groupId":"OG001","value":"2.0"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Fever: 39.0-<39.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1052"},{"groupId":"OG001","value":"2088"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0"},{"groupId":"OG001","value":"0.5"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Fever: 39.5-<40.0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1052"},{"groupId":"OG001","value":"2088"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"0.4"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Fever: 40.0-<40.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1052"},{"groupId":"OG001","value":"2088"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0951"},{"groupId":"OG001","value":"0.0479"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Fever: 40.5-<41.0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1052"},{"groupId":"OG001","value":"2088"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0951"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age >=6 Years; After First Vaccination; Fever: >=41.0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1052"},{"groupId":"OG001","value":"2088"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Headache: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1117"},{"groupId":"OG001","value":"2248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.2"},{"groupId":"OG001","value":"10.4"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Headache: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1117"},{"groupId":"OG001","value":"2248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9"},{"groupId":"OG001","value":"3.5"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Headache: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1117"},{"groupId":"OG001","value":"2248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1"},{"groupId":"OG001","value":"1.3"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Asthenia: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1117"},{"groupId":"OG001","value":"2248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"6.6"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Asthenia: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1117"},{"groupId":"OG001","value":"2248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"},{"groupId":"OG001","value":"1.9"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Asthenia: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1117"},{"groupId":"OG001","value":"2248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"0.7"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Malaise: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1117"},{"groupId":"OG001","value":"2248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.8"},{"groupId":"OG001","value":"8.1"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Malaise: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1117"},{"groupId":"OG001","value":"2248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"},{"groupId":"OG001","value":"1.9"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Malaise: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1117"},{"groupId":"OG001","value":"2248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"},{"groupId":"OG001","value":"1.0"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Muscle Pain: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1117"},{"groupId":"OG001","value":"2248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.6"},{"groupId":"OG001","value":"10.7"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Muscle Pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1117"},{"groupId":"OG001","value":"2248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"},{"groupId":"OG001","value":"2.0"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Muscle Pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1117"},{"groupId":"OG001","value":"2248"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"0.9"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Fever: 38.0-<38.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1056"},{"groupId":"OG001","value":"2142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4"},{"groupId":"OG001","value":"2.0"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Fever: 38.5-<39.0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1056"},{"groupId":"OG001","value":"2142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"},{"groupId":"OG001","value":"1.5"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Fever: 39.0-<39.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1056"},{"groupId":"OG001","value":"2142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1"},{"groupId":"OG001","value":"0.7"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Fever: 39.5-<40.0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1056"},{"groupId":"OG001","value":"2142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"0.5"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Fever: 40.0-<40.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1056"},{"groupId":"OG001","value":"2142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.0467"}]}]},{"title":"Children of Age >=6 Years; After Second Vaccination; Fever: >=40.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1056"},{"groupId":"OG001","value":"2142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any Unsolicited Adverse Events (AEs) in the Safety Set Immunogenicity Subset","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study. Percentages were rounded off to the nearest single decimal place.","populationDescription":"The SS-Immunogenicity Subset included all randomized participants in the safety/immunogenicity subset who received at least 1 dose of the trial vaccines (TDV or placebo). Number analyzed is the number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 1 through 28 after each vaccination on Day 1 (Month 0) and Day 90 (Month 3)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1329"},{"groupId":"OG001","value":"2663"}]}],"classes":[{"title":"After First Vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1329"},{"groupId":"OG001","value":"2663"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.6"},{"groupId":"OG001","value":"11.1"}]}]},{"title":"After Second Vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1301"},{"groupId":"OG001","value":"2606"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.2"},{"groupId":"OG001","value":"9.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serious Adverse Events (SAEs) During Parts 1 and 2","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. Percentages were rounded off to the nearest single decimal place. In the category 'Part 1 and 2 combined' participants are counted only once even if they experienced events in both Part 1 and Part 2 in order to yield total of unique participants who had SAEs.","populationDescription":"The SS included all randomized participants who received at least one dose of the investigational product (IP) (TDV or placebo). Number analyzed is the number of participants at risk at the start of the specified analysis period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From Day 1 until the end of Parts 1 (Month 15) and 2 (Month 21)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6687"},{"groupId":"OG001","value":"13380"}]}],"classes":[{"title":"Part 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6687"},{"groupId":"OG001","value":"13380"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8"},{"groupId":"OG001","value":"3.1"}]}]},{"title":"Part 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6519"},{"groupId":"OG001","value":"13033"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"},{"groupId":"OG001","value":"1.2"}]}]},{"title":"Parts 1 and 2 Combined","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6687"},{"groupId":"OG001","value":"13380"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.9"},{"groupId":"OG001","value":"4.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Fatal SAEs and SAEs Related to Study Drug During the First and Second Half of Part 3","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation.","populationDescription":"The SS included all randomized participants who received at least one dose of the IP (TDV or placebo). Overall number of participants analyzed are the number of participants with data available for analyses. Number analyzed is the number of participants at risk at the start of the specified analysis period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"First and Second half (18 months each) of Part 3 (up to 3 years, beginning at Month 22)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 ml, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6487"},{"groupId":"OG001","value":"12961"}]}],"classes":[{"title":"Fatal SAEs: First Half of Part 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6487"},{"groupId":"OG001","value":"12961"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0308"},{"groupId":"OG001","value":"0.0386"}]}]},{"title":"SAEs Related to Study Drug: First Half of Part 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6487"},{"groupId":"OG001","value":"12961"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Fatal SAEs: Second Half of Part 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6340"},{"groupId":"OG001","value":"12660"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0631"},{"groupId":"OG001","value":"0.0474"}]}]},{"title":"SAEs Related to Study Drug: Second Half of Part 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6340"},{"groupId":"OG001","value":"12660"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Seropositivity Rate for Each of the Four Dengue Serotypes in the Immunogenicity Subset","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The four DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation.","populationDescription":"Per-Protocol Set for Immunogenicity (PPSI): all participants in Full Analysis Set for Immunogenicity (FASI) who had no major protocol violations. The FASI were based on FAS \\& included all randomized participants in subset for whom a valid pre-dosing and at least one valid post-dosing blood sample have been received for immunogenicity. Number analyzed is the number of participants with data available for analysis at the specified time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Pre-vaccination on Day 1 (Baseline), post-first vaccination on Month 1, pre-vaccination on Month 3; post-second vaccination at Months 4, 9 and 15, and then annually (up to 3 years)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2518"}]}],"classes":[{"title":"Baseline: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2518"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.5"},{"groupId":"OG001","value":"64.3"}]}]},{"title":"Baseline: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2517"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.3"},{"groupId":"OG001","value":"69.6"}]}]},{"title":"Baseline: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2517"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.7"},{"groupId":"OG001","value":"63.5"}]}]},{"title":"Baseline: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2518"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.2"},{"groupId":"OG001","value":"63.5"}]}]},{"title":"Month 1: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1165"},{"groupId":"OG001","value":"2353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.0"},{"groupId":"OG001","value":"98.0"}]}]},{"title":"Month 1: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1164"},{"groupId":"OG001","value":"2353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.0"},{"groupId":"OG001","value":"99.5"}]}]},{"title":"Month 1: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1164"},{"groupId":"OG001","value":"2353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.0"},{"groupId":"OG001","value":"98.7"}]}]},{"title":"Month 1: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1165"},{"groupId":"OG001","value":"2353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.7"},{"groupId":"OG001","value":"97.1"}]}]},{"title":"Month 3: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1244"},{"groupId":"OG001","value":"2515"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.9"},{"groupId":"OG001","value":"97.1"}]}]},{"title":"Month 3: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1244"},{"groupId":"OG001","value":"2515"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.2"},{"groupId":"OG001","value":"99.7"}]}]},{"title":"Month 3: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1243"},{"groupId":"OG001","value":"2515"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.6"},{"groupId":"OG001","value":"98.1"}]}]},{"title":"Month 3: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1244"},{"groupId":"OG001","value":"2515"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.6"},{"groupId":"OG001","value":"97.3"}]}]},{"title":"Month 4: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1131"},{"groupId":"OG001","value":"2262"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.6"},{"groupId":"OG001","value":"99.8"}]}]},{"title":"Month 4: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1131"},{"groupId":"OG001","value":"2262"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.8"},{"groupId":"OG001","value":"99.912"}]}]},{"title":"Month 4: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1131"},{"groupId":"OG001","value":"2262"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.0"},{"groupId":"OG001","value":"99.9"}]}]},{"title":"Month 4: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1131"},{"groupId":"OG001","value":"2262"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.2"},{"groupId":"OG001","value":"99.912"}]}]},{"title":"Month 9: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1085"},{"groupId":"OG001","value":"2196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.5"},{"groupId":"OG001","value":"98.3"}]}]},{"title":"Month 9: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1085"},{"groupId":"OG001","value":"2196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.5"},{"groupId":"OG001","value":"100.0"}]}]},{"title":"Month 9: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1085"},{"groupId":"OG001","value":"2196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.2"},{"groupId":"OG001","value":"98.8"}]}]},{"title":"Month 9: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1085"},{"groupId":"OG001","value":"2196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.2"},{"groupId":"OG001","value":"99.0"}]}]},{"title":"Month 15: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1115"},{"groupId":"OG001","value":"2213"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.7"},{"groupId":"OG001","value":"97.6"}]}]},{"title":"Month 15: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1115"},{"groupId":"OG001","value":"2214"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.4"},{"groupId":"OG001","value":"99.955"}]}]},{"title":"Month 15: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1115"},{"groupId":"OG001","value":"2215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.3"},{"groupId":"OG001","value":"97.7"}]}]},{"title":"Month 15: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1115"},{"groupId":"OG001","value":"2215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.0"},{"groupId":"OG001","value":"98.4"}]}]},{"title":"Year 1: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"},{"groupId":"OG001","value":"1904"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.6"},{"groupId":"OG001","value":"97.0"}]}]},{"title":"Year 1: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"},{"groupId":"OG001","value":"1904"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.0"},{"groupId":"OG001","value":"99.9"}]}]},{"title":"Year 1: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"},{"groupId":"OG001","value":"1904"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.5"},{"groupId":"OG001","value":"97.3"}]}]},{"title":"Year 1: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"},{"groupId":"OG001","value":"1904"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.6"},{"groupId":"OG001","value":"98.3"}]}]},{"title":"Year 2: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"1921"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.5"},{"groupId":"OG001","value":"95.7"}]}]},{"title":"Year 2: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"1921"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.7"},{"groupId":"OG001","value":"99.948"}]}]},{"title":"Year 2: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"1921"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.8"},{"groupId":"OG001","value":"95.5"}]}]},{"title":"Year 2: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"1921"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.7"},{"groupId":"OG001","value":"98.0"}]}]},{"title":"Year 3: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1023"},{"groupId":"OG001","value":"2049"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.5"},{"groupId":"OG001","value":"94.9"}]}]},{"title":"Year 3: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1023"},{"groupId":"OG001","value":"2049"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.5"},{"groupId":"OG001","value":"99.9"}]}]},{"title":"Year 3: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1023"},{"groupId":"OG001","value":"2049"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.2"},{"groupId":"OG001","value":"95.7"}]}]},{"title":"Year 3: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1023"},{"groupId":"OG001","value":"2049"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.1"},{"groupId":"OG001","value":"96.0"}]}]}]},{"type":"SECONDARY","title":"Seropositivity Rate for Multiple Dengue Serotypes in the Immunogenicity Subset","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for any one (monovalent), two (bivalent), three (trivalent), and four (tetravalent) dengue serotypes, as well as at least bivalent (seropositive for ≥2 dengue serotypes) and at least trivalent (seropositive for ≥3 dengue serotypes), is derived from the titers of dengue-neutralizing antibodies. Seropositive response is defined as a reciprocal neutralizing titer ≥ 10. The four DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation.","populationDescription":"PPSI: all participants in FASI who had no major protocol violations. The FASI were based on FAS \\& included all randomized participants in subset for whom a valid pre-dosing and at least one valid post-dosing blood sample have been received for immunogenicity. Number analyzed is the number of participants with data available for analysis at the specified time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Pre-vaccination on Day 1 (Baseline), post-first vaccination on Month 1, pre-vaccination on Month 3; post-second vaccination at Months 4, 9 and 15, and then annually (up to 3 years)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2518"}]}],"classes":[{"title":"Baseline: Monovalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2518"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.5"},{"groupId":"OG001","value":"6.6"}]}]},{"title":"Baseline: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2518"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8"},{"groupId":"OG001","value":"2.4"}]}]},{"title":"Baseline: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2517"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.7"},{"groupId":"OG001","value":"2.9"}]}]},{"title":"Baseline: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2517"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.4"},{"groupId":"OG001","value":"60.2"}]}]},{"title":"Baseline: At Least Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2518"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.9"},{"groupId":"OG001","value":"65.5"}]}]},{"title":"Baseline: At Least Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2517"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.1"},{"groupId":"OG001","value":"63.1"}]}]},{"title":"Month 1: Monovalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1165"},{"groupId":"OG001","value":"2353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.4"},{"groupId":"OG001","value":"0.3"}]}]},{"title":"Month 1: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1165"},{"groupId":"OG001","value":"2353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.8"},{"groupId":"OG001","value":"0.6"}]}]},{"title":"Month 1: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1164"},{"groupId":"OG001","value":"2353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.2"},{"groupId":"OG001","value":"3.7"}]}]},{"title":"Month 1: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1164"},{"groupId":"OG001","value":"2353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"59.8"},{"groupId":"OG001","value":"95.2"}]}]},{"title":"Month 1: At Least Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1165"},{"groupId":"OG001","value":"2353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.8"},{"groupId":"OG001","value":"99.4"}]}]},{"title":"Month 1: At Least Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1164"},{"groupId":"OG001","value":"2353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.0"},{"groupId":"OG001","value":"98.9"}]}]},{"title":"Month 3: Monovalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1244"},{"groupId":"OG001","value":"2515"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.8"},{"groupId":"OG001","value":"0.4"}]}]},{"title":"Month 3: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1244"},{"groupId":"OG001","value":"2515"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.1"},{"groupId":"OG001","value":"1.1"}]}]},{"title":"Month 3: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1244"},{"groupId":"OG001","value":"2515"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.1"},{"groupId":"OG001","value":"3.7"}]}]},{"title":"Month 3: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1243"},{"groupId":"OG001","value":"2515"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.8"},{"groupId":"OG001","value":"94.6"}]}]},{"title":"Month 3: At Least Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1244"},{"groupId":"OG001","value":"2515"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.0"},{"groupId":"OG001","value":"99.4"}]}]},{"title":"Month 3: At Least Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1244"},{"groupId":"OG001","value":"2515"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.8"},{"groupId":"OG001","value":"98.3"}]}]},{"title":"Month 4: Monovalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1131"},{"groupId":"OG001","value":"2262"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.6"},{"groupId":"OG001","value":"0"}]}]},{"title":"Month 4: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1131"},{"groupId":"OG001","value":"2262"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6"},{"groupId":"OG001","value":"0.088"}]}]},{"title":"Month 4: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1131"},{"groupId":"OG001","value":"2262"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"0.1"}]}]},{"title":"Month 4: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1131"},{"groupId":"OG001","value":"2262"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.6"},{"groupId":"OG001","value":"99.7"}]}]},{"title":"Month 4: At Least Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1131"},{"groupId":"OG001","value":"2262"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.6"},{"groupId":"OG001","value":"99.956"}]}]},{"title":"Month 4: At Least Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1131"},{"groupId":"OG001","value":"2262"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.1"},{"groupId":"OG001","value":"99.9"}]}]},{"title":"Month 9: Monovalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1085"},{"groupId":"OG001","value":"2196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.7"},{"groupId":"OG001","value":"0.091"}]}]},{"title":"Month 9: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1085"},{"groupId":"OG001","value":"2196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4"},{"groupId":"OG001","value":"0.8"}]}]},{"title":"Month 9: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1085"},{"groupId":"OG001","value":"2196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"2.1"}]}]},{"title":"Month 9: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1085"},{"groupId":"OG001","value":"2196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.7"},{"groupId":"OG001","value":"97.0"}]}]},{"title":"Month 9: At Least Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1085"},{"groupId":"OG001","value":"2196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.1"},{"groupId":"OG001","value":"99.909"}]}]},{"title":"Month 9: At Least Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1085"},{"groupId":"OG001","value":"2196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.7"},{"groupId":"OG001","value":"99.1"}]}]},{"title":"Month 15: Monovalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1115"},{"groupId":"OG001","value":"2215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9"},{"groupId":"OG001","value":"0.5"}]}]},{"title":"Month 15: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1115"},{"groupId":"OG001","value":"2215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.6"},{"groupId":"OG001","value":"1.4"}]}]},{"title":"Month 15: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1115"},{"groupId":"OG001","value":"2214"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1"},{"groupId":"OG001","value":"2.2"}]}]},{"title":"Month 15: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1115"},{"groupId":"OG001","value":"2213"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.8"},{"groupId":"OG001","value":"96.0"}]}]},{"title":"Month 15: At Least Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1115"},{"groupId":"OG001","value":"2215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.4"},{"groupId":"OG001","value":"99.5"}]}]},{"title":"Month 15: At Least Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1115"},{"groupId":"OG001","value":"2214"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.8"},{"groupId":"OG001","value":"98.1"}]}]},{"title":"Year 1: Monovalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"},{"groupId":"OG001","value":"1904"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5"},{"groupId":"OG001","value":"0.7"}]}]},{"title":"Year 1: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"},{"groupId":"OG001","value":"1904"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"1.5"}]}]},{"title":"Year 1: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"},{"groupId":"OG001","value":"1904"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.2"},{"groupId":"OG001","value":"2.2"}]}]},{"title":"Year 1: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"},{"groupId":"OG001","value":"1904"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.9"},{"groupId":"OG001","value":"95.5"}]}]},{"title":"Year 1: At Least Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"},{"groupId":"OG001","value":"1904"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.1"},{"groupId":"OG001","value":"99.3"}]}]},{"title":"Year 1: At Least Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"},{"groupId":"OG001","value":"1904"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.2"},{"groupId":"OG001","value":"97.7"}]}]},{"title":"Year 2: Monovalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"1921"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9"},{"groupId":"OG001","value":"1.1"}]}]},{"title":"Year 2: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"1921"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"1.9"}]}]},{"title":"Year 2: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"1921"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"},{"groupId":"OG001","value":"3.7"}]}]},{"title":"Year 2: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"1921"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.9"},{"groupId":"OG001","value":"93.3"}]}]},{"title":"Year 2: At Least Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"1921"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.1"},{"groupId":"OG001","value":"98.9"}]}]},{"title":"Year 2: At Least Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"1921"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.6"},{"groupId":"OG001","value":"97.0"}]}]},{"title":"Year 3:Monovalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1023"},{"groupId":"OG001","value":"2049"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6"},{"groupId":"OG001","value":"1.6"}]}]},{"title":"Year 3: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1023"},{"groupId":"OG001","value":"2049"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"2.4"}]}]},{"title":"Year 3:Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1023"},{"groupId":"OG001","value":"2049"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"3.7"}]}]},{"title":"Year 3:Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1023"},{"groupId":"OG001","value":"2049"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.3"},{"groupId":"OG001","value":"92.3"}]}]},{"title":"Year 3:At Least Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1023"},{"groupId":"OG001","value":"2049"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.7"},{"groupId":"OG001","value":"98.3"}]}]},{"title":"Year 3:At Least Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1023"},{"groupId":"OG001","value":"2049"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.9"},{"groupId":"OG001","value":"95.9"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the Four Dengue Serotypes in the Immunogenicity Subset","description":"GMTs of neutralizing antibodies were measured via microneutralization test 50% (MNT50). The four DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.","populationDescription":"PPSI: all participants in FASI who had no major protocol violations. The FASI were based on FAS \\& included all randomized participants in subset for whom a valid pre-dosing and at least one valid post-dosing blood sample have been received for immunogenicity. Number analyzed is the number of participants with data available for analysis at the specified time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titres","timeFrame":"Pre-vaccination on Day 1 (Baseline), post-first vaccination on Month 1, pre-vaccination on Month 3; post-second vaccination at Months 4, 9 and 15, and then annually (up to 3 years)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2518"}]}],"classes":[{"title":"Baseline: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2518"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"128.6","lowerLimit":"109.3","upperLimit":"151.4"},{"groupId":"OG001","value":"120.3","lowerLimit":"107.3","upperLimit":"134.8"}]}]},{"title":"Baseline: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2517"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"197.4","lowerLimit":"167.8","upperLimit":"232.2"},{"groupId":"OG001","value":"186.0","lowerLimit":"165.9","upperLimit":"208.4"}]}]},{"title":"Baseline: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2517"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"109.4","lowerLimit":"93.8","upperLimit":"127.6"},{"groupId":"OG001","value":"108.7","lowerLimit":"97.6","upperLimit":"121.1"}]}]},{"title":"Baseline: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1247"},{"groupId":"OG001","value":"2518"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","lowerLimit":"70.2","upperLimit":"93.1"},{"groupId":"OG001","value":"76.2","lowerLimit":"69.2","upperLimit":"83.9"}]}]},{"title":"Month 1: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1165"},{"groupId":"OG001","value":"2353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"127.5","lowerLimit":"107.7","upperLimit":"150.9"},{"groupId":"OG001","value":"1031.5","lowerLimit":"944.4","upperLimit":"1126.6"}]}]},{"title":"Month 1: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1164"},{"groupId":"OG001","value":"2353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"197.2","lowerLimit":"166.7","upperLimit":"233.4"},{"groupId":"OG001","value":"6575.7","lowerLimit":"6237.2","upperLimit":"6932.5"}]}]},{"title":"Month 1: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1164"},{"groupId":"OG001","value":"2353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"108.6","lowerLimit":"92.8","upperLimit":"127.1"},{"groupId":"OG001","value":"1133.8","lowerLimit":"1050.4","upperLimit":"1223.8"}]}]},{"title":"Month 1: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1165"},{"groupId":"OG001","value":"2353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","lowerLimit":"67.2","upperLimit":"89.7"},{"groupId":"OG001","value":"653.4","lowerLimit":"607.0","upperLimit":"703.4"}]}]},{"title":"Month 3: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1244"},{"groupId":"OG001","value":"2515"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"126.3","lowerLimit":"107.9","upperLimit":"148.0"},{"groupId":"OG001","value":"828.7","lowerLimit":"760.6","upperLimit":"902.8"}]}]},{"title":"Month 3: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1244"},{"groupId":"OG001","value":"2515"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"201.0","lowerLimit":"171.3","upperLimit":"236.0"},{"groupId":"OG001","value":"3598.5","lowerLimit":"3425.0","upperLimit":"3780.8"}]}]},{"title":"Month 3: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1243"},{"groupId":"OG001","value":"2515"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"103.9","lowerLimit":"89.5","upperLimit":"120.7"},{"groupId":"OG001","value":"714.2","lowerLimit":"661.1","upperLimit":"771.6"}]}]},{"title":"Month 3: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1244"},{"groupId":"OG001","value":"2515"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","lowerLimit":"67.8","upperLimit":"89.3"},{"groupId":"OG001","value":"463.9","lowerLimit":"431.3","upperLimit":"498.9"}]}]},{"title":"Month 4: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1131"},{"groupId":"OG001","value":"2262"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"139.0","lowerLimit":"117.6","upperLimit":"164.3"},{"groupId":"OG001","value":"1059.2","lowerLimit":"981.6","upperLimit":"1143.0"}]}]},{"title":"Month 4: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1131"},{"groupId":"OG001","value":"2262"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"215.3","lowerLimit":"181.7","upperLimit":"255.0"},{"groupId":"OG001","value":"3646.7","lowerLimit":"3480.0","upperLimit":"3821.3"}]}]},{"title":"Month 4: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1131"},{"groupId":"OG001","value":"2262"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"114.5","lowerLimit":"97.7","upperLimit":"134.3"},{"groupId":"OG001","value":"986.7","lowerLimit":"924.5","upperLimit":"1053.0"}]}]},{"title":"Month 4: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1131"},{"groupId":"OG001","value":"2262"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.2","lowerLimit":"74.5","upperLimit":"99.8"},{"groupId":"OG001","value":"630.0","lowerLimit":"593.2","upperLimit":"668.9"}]}]},{"title":"Month 9: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1085"},{"groupId":"OG001","value":"2196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"130.5","lowerLimit":"110.3","upperLimit":"154.4"},{"groupId":"OG001","value":"666.6","lowerLimit":"611.8","upperLimit":"726.2"}]}]},{"title":"Month 9: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1085"},{"groupId":"OG001","value":"2196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"225.7","lowerLimit":"190.5","upperLimit":"267.3"},{"groupId":"OG001","value":"2521.0","lowerLimit":"2392.4","upperLimit":"2656.5"}]}]},{"title":"Month 9: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1085"},{"groupId":"OG001","value":"2196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"105.3","lowerLimit":"89.9","upperLimit":"123.3"},{"groupId":"OG001","value":"513.0","lowerLimit":"474.2","upperLimit":"555.1"}]}]},{"title":"Month 9: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1085"},{"groupId":"OG001","value":"2196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.4","lowerLimit":"72.9","upperLimit":"97.8"},{"groupId":"OG001","value":"390.0","lowerLimit":"363.6","upperLimit":"418.4"}]}]},{"title":"Month 15: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1115"},{"groupId":"OG001","value":"2213"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"139.2","lowerLimit":"117.6","upperLimit":"164.7"},{"groupId":"OG001","value":"584.1","lowerLimit":"534.9","upperLimit":"637.8"}]}]},{"title":"Month 15: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1115"},{"groupId":"OG001","value":"2214"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"211.8","lowerLimit":"178.5","upperLimit":"251.3"},{"groupId":"OG001","value":"1977.3","lowerLimit":"1871.7","upperLimit":"2088.8"}]}]},{"title":"Month 15: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1115"},{"groupId":"OG001","value":"2215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","lowerLimit":"83.3","upperLimit":"113.5"},{"groupId":"OG001","value":"383.9","lowerLimit":"354.0","upperLimit":"416.3"}]}]},{"title":"Month 15: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1115"},{"groupId":"OG001","value":"2215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.9","lowerLimit":"86.0","upperLimit":"116.0"},{"groupId":"OG001","value":"408.0","lowerLimit":"379.6","upperLimit":"438.6"}]}]},{"title":"Year 1: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"},{"groupId":"OG001","value":"1904"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"161.3","lowerLimit":"134.6","upperLimit":"193.3"},{"groupId":"OG001","value":"567.8","lowerLimit":"516.0","upperLimit":"624.7"}]}]},{"title":"Year 1: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"},{"groupId":"OG001","value":"1904"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"183.1","lowerLimit":"154.0","upperLimit":"217.7"},{"groupId":"OG001","value":"1123.9","lowerLimit":"1054.1","upperLimit":"1198.3"}]}]},{"title":"Year 1: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"},{"groupId":"OG001","value":"1904"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"111.0","lowerLimit":"94.1","upperLimit":"130.9"},{"groupId":"OG001","value":"377.7","lowerLimit":"346.2","upperLimit":"412.2"}]}]},{"title":"Year 1: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"},{"groupId":"OG001","value":"1904"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","lowerLimit":"84.6","upperLimit":"115.0"},{"groupId":"OG001","value":"345.0","lowerLimit":"319.6","upperLimit":"372.5"}]}]},{"title":"Year 2: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"1921"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"205.1","lowerLimit":"170.9","upperLimit":"246.1"},{"groupId":"OG001","value":"513.2","lowerLimit":"465.9","upperLimit":"565.3"}]}]},{"title":"Year 2: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"1921"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"208.1","lowerLimit":"175.3","upperLimit":"246.9"},{"groupId":"OG001","value":"896.4","lowerLimit":"839.2","upperLimit":"957.5"}]}]},{"title":"Year 2: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"1921"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"127.5","lowerLimit":"108.2","upperLimit":"150.2"},{"groupId":"OG001","value":"323.2","lowerLimit":"295.7","upperLimit":"353.2"}]}]},{"title":"Year 2: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"1921"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"110.4","lowerLimit":"94.8","upperLimit":"128.4"},{"groupId":"OG001","value":"283.8","lowerLimit":"262.9","upperLimit":"306.4"}]}]},{"title":"Year 3: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1023"},{"groupId":"OG001","value":"2049"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"213.3","lowerLimit":"179.4","upperLimit":"253.6"},{"groupId":"OG001","value":"483.1","lowerLimit":"440.7","upperLimit":"529.7"}]}]},{"title":"Year 3: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1023"},{"groupId":"OG001","value":"2049"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"193.6","lowerLimit":"164.6","upperLimit":"227.6"},{"groupId":"OG001","value":"727.5","lowerLimit":"682.4","upperLimit":"775.5"}]}]},{"title":"Year 3: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1023"},{"groupId":"OG001","value":"2049"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"139.8","lowerLimit":"119.3","upperLimit":"163.7"},{"groupId":"OG001","value":"327.9","lowerLimit":"301.4","upperLimit":"356.8"}]}]},{"title":"Year 3: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1023"},{"groupId":"OG001","value":"2049"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"107.6","lowerLimit":"93.1","upperLimit":"124.4"},{"groupId":"OG001","value":"244.4","lowerLimit":"226.7","upperLimit":"263.6"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases due to virologically-confirmed dengue fever that occurred during the first half of Part 3.","populationDescription":"PPS included all participants in the FAS who had no major protocol violations. FAS included all randomized participants who received at least 1 dose of the trial vaccines. Overall number of participants analyzed is the number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"First half of Part 3 (18 months beginning at Month 22)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 ml, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6236"},{"groupId":"OG001","value":"12510"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"252"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"47.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"37.1","ciUpperLimit":"56.0","estimateComment":"VE and two-sided 95% CIs are estimated from a Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region"}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases due to virologically-confirmed dengue fever that occurred during the second half of Part 3.","populationDescription":"PPS included all participants in the FAS who had no major protocol violations. FAS included all randomized participants who received at least 1 dose of the trial vaccines. Overall number of participants analyzed is the number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"Second half of Part 3 (18 months beginning at Month 40)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6102"},{"groupId":"OG001","value":"12224"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"49"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"55.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"34.5","ciUpperLimit":"70.0","estimateComment":"VE and two-sided 95% CIs are estimated from a Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of Two Doses of TDV in Preventing Hospitalization Due to Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases requiring hospitalization due to virologically-confirmed dengue fever that occurred during the first half of Part 3.","populationDescription":"PPS included all participants in the FAS who had no major protocol violations. FAS included all randomized participants who received at least 1 dose of the trial vaccines. Overall number of participants analyzed is the number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"First half of Part 3 (18 months beginning at Month 22)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 ml, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6236"},{"groupId":"OG001","value":"12510"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"24"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"73.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"56.3","ciUpperLimit":"83.9","estimateComment":"VE and two-sided 95% CIs are estimated from a Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of Two Doses of TDV in Preventing Hospitalization Due to Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases requiring hospitalization due to virologically-confirmed dengue fever that occurred during the second half of Part 3.","populationDescription":"PPS included all participants in the FAS who had no major protocol violations. FAS included all randomized participants who received at least 1 dose of the trial vaccines. Overall number of participants analyzed is the number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"Second half of Part 3 (18 months beginning at Month 40)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6102"},{"groupId":"OG001","value":"12224"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"93.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"72.4","ciUpperLimit":"98.6","estimateComment":"VE and two-sided 95% CIs are estimated from a Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype From 30 Days Post-Booster Vaccination (Day 30 Booster [b] (Month 1b)) Until the End of Part 4","description":"The VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases.","populationDescription":"The Per-Protocol Set-Booster (PPS-B) included all participants in the FAS-B who had no major protocol violations. The Full Analysis Set-Booster (FAS-B) included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-booster vaccination (Day 30 booster [b] (Month 1b)) until the end of Part 4 (Month 13b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2981"},{"groupId":"OG001","value":"5966"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"39"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"79.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"70.1","ciUpperLimit":"85.9","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Each Dengue Serotype From 30 Days Post-Booster Vaccination (Day 30b [Month 1b]) Until the End of Part 4","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 4 (Month 13b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2981"},{"groupId":"OG001","value":"5966"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"15"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"9"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"12"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"DENV-1","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"76.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"57.1","ciUpperLimit":"87.4","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-2","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"85.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"69.9","ciUpperLimit":"93.2","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-3","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"62","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-69.7","ciUpperLimit":"91.5","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-4","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"77.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"54.8","ciUpperLimit":"88.5","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Any And Each Dengue Serotype in Dengue Seronegative Participants at Baseline From 30 Days Post-Booster Vaccination (Day 30b [Month 1b]) Until the End of Part 4","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted only once for the \"Any Dengue Serotype\" category but counted separately for each dengue serotype they belong to.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo). Overall number of participants analyzed is the number of participants with seronegative baseline status and with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 4 (Month 13b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"986"},{"groupId":"OG001","value":"1928"}]}],"classes":[{"title":"Any Dengue Serotype","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"11"}]}]},{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"4"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Any Dengue Serotype","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"79.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"57.8","ciUpperLimit":"89.7","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-1","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"57.6","ciUpperLimit":"95.4","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-2","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"89.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"13.5","ciUpperLimit":"98.8","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-3","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"42.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-307.5","ciUpperLimit":"92.0","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-4","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"61","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-45.1","ciUpperLimit":"89.5","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Any and Each Dengue Serotype in Dengue Seropositive Participants at Baseline From 30 Days Post-Booster Vaccination (Day 30b [Month 1b]) Until the End of Part 4","description":"VE is defined as 1 - (λv/λC), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted only once for the \"Any Dengue Serotype\" category but counted separately for each dengue serotype they belong to.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo). Overall number of participants analyzed is the number of participants with seropositive baseline status and with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 4 (Month 13b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1995"},{"groupId":"OG001","value":"4036"}]}],"classes":[{"title":"Any Dengue Serotype","categories":[{"measurements":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"28"}]}]},{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"8"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Any Dengue Serotype","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"79.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"68.3","ciUpperLimit":"86.9","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-1","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"69.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"36.4","ciUpperLimit":"85.8","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-2","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"84.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"66.6","ciUpperLimit":"93.2","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-3","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"75.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-168.8","ciUpperLimit":"97.8","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"81","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"57.2","ciUpperLimit":"91.6","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Hospitalization Due to Virologically Confirmed Dengue Fever Induced by Any Dengue Serotype From 30 Days Post-Booster Vaccination (Day 30b [Month 1b]) Until the End of Part 4","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases requiring hospitalization due to virologically-confirmed dengue fever.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 4 (Month 13b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2981"},{"groupId":"OG001","value":"5966"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"93.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"79.3","ciUpperLimit":"98.1","estimateComment":"VE and two-sided 95% CIs are estimated from a Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Severe Dengue Fever Induced by Any Dengue Serotype From 30 Days Post-Booster Vaccination (Day 30b [Month 1b]) Until the End of Part 4","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. Severe cases were determined by Adjudication Committee. VE was assessed using the number of severe cases due to virologically-confirmed dengue fever.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 4 (Month 13b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2981"},{"groupId":"OG001","value":"5966"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"100","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-849.4","ciUpperLimit":"100.0","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype During Part 5","description":"The VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted only once for the any dengue serotype.","populationDescription":"The Per-Protocol Set-Booster (PPS-B) included all participants in the FAS-B who had no major protocol violations. The Full Analysis Set-Booster (FAS-B) included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From Month 14b until the end of Part 5 (Month 25b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2935"},{"groupId":"OG001","value":"5865"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"45"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"67.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"52.1","ciUpperLimit":"77.5","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Each Dengue Serotype During Part 5","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted separately for each dengue serotype.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From Month 14b until the end of Part 5 (Month 25b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2935"},{"groupId":"OG001","value":"5865"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"17"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"20"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"DENV-1","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"56.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"16.2","ciUpperLimit":"77.4","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-2","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"86.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"63.8","ciUpperLimit":"95.0","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-3","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"51.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"9.9","ciUpperLimit":"73.9","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-4","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"85.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"47.4","ciUpperLimit":"96.0","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Any And Each Dengue Serotype in Dengue Seronegative Participants at Baseline During Part 5","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted only once for the \"Any Dengue Serotype\" category but counted separately for each dengue serotype they belong to.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo). Overall number of participants analyzed is the number of participants with seronegative baseline status and with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From Month 14b until the end of Part 5 (Month 25b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"974"},{"groupId":"OG001","value":"1908"}]}],"classes":[{"title":"Any Dengue Serotype","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"}]}]},{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Any Dengue Serotype","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"70.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"39.1","ciUpperLimit":"85.5","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-1","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"57.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-27.2","ciUpperLimit":"85.7","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-2","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"90","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"14.0","ciUpperLimit":"98.8","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-3","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"36.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-138.1","ciUpperLimit":"82.9","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-4","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"100","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"43.1","ciUpperLimit":"100.0","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Any and Each Dengue Serotype in Dengue Seropositive Participants at Baseline During Part 5","description":"VE is defined as 1 - (λv/λC), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted only once for the \"Any Dengue Serotype\" category but counted separately for each dengue serotype they belong to.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo). Overall number of participants analyzed is the number of participants with seropositive baseline status and with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From Month 14b until the end of Part 5 (Month 25b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1961"},{"groupId":"OG001","value":"3955"}]}],"classes":[{"title":"Any Dengue Serotype","categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"33"}]}]},{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"15"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Any Dengue Serotype","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"65.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"46.4","ciUpperLimit":"78.1","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-1","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"56.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.8","ciUpperLimit":"80.7","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-2","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"85.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"54.4","ciUpperLimit":"95.2","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-3","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"54.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"8.3","ciUpperLimit":"77.6","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"75.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.2","ciUpperLimit":"93.9","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Hospitalization Due to Virologically Confirmed Dengue Fever Induced by Any Dengue Serotype During Part 5","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases requiring hospitalization due to virologically-confirmed dengue fever.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From Month 14b until the end of Part 5 (Month 25b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2935"},{"groupId":"OG001","value":"5865"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"84.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"53.7","ciUpperLimit":"95.1","estimateComment":"VE and two-sided 95% CIs are estimated from a Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Severe Dengue Fever Induced by Any Dengue Serotype During Part 5","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. Severe cases were determined by Adjudication Committee. VE was assessed using the number of severe cases due to virologically-confirmed dengue fever.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From Month 14b until the end of Part 5 (Month 25b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2935"},{"groupId":"OG001","value":"5865"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype for Parts 4 And 5 Combined","description":"The VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b) until the end of Part 5 (Month 25b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2981"},{"groupId":"OG001","value":"5966"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"84"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"74.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"66.6","ciUpperLimit":"80.3","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Each Dengue Serotype for Parts 4 And 5 Combined","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 5 (Month 25b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2981"},{"groupId":"OG001","value":"5966"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"32"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"14"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"23"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"15"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"DENV-1","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"51.7","ciUpperLimit":"80.0","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-2","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"85.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"74.5","ciUpperLimit":"92.2","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-3","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"54.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"19.1","ciUpperLimit":"73.9","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-4","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"79.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"62.4","ciUpperLimit":"88.7","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Any And Each Dengue Serotype in Dengue Seronegative Participants at Baseline for Parts 4 And 5 Combined","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted only once for the \"Any Dengue Serotype\" category but counted separately for each dengue serotype they belong to.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo). Overall number of participants analyzed is the number of participants with seronegative baseline status and with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 5 (Month 25b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"986"},{"groupId":"OG001","value":"1928"}]}],"classes":[{"title":"Any Dengue Serotype","categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"23"}]}]},{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"10"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"2"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Any Dengue Serotype","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"75.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"59.3","ciUpperLimit":"85.0","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-1","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"76.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"50.0","ciUpperLimit":"88.9","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-2","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"89.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"53.7","ciUpperLimit":"97.8","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-3","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"37.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-84.9","ciUpperLimit":"79.2","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-4","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"78.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"29.7","ciUpperLimit":"93.3","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Dengue Fever Induced by Any and Each Dengue Serotype in Dengue Seropositive Participants at Baseline for Parts 4 And 5 Combined","description":"VE is defined as 1 - (λv/λC), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of virologically-confirmed dengue fever cases. Participants are counted only once for the \"Any Dengue Serotype\" category but counted separately for each dengue serotype they belong to.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo). Overall number of participants analyzed is the number of participants with seropositive baseline status and with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 5 (Month 25b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1995"},{"groupId":"OG001","value":"4036"}]}],"classes":[{"title":"Any Dengue Serotype","categories":[{"measurements":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"61"}]}]},{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"22"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"12"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"16"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"11"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Any Dengue Serotype","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"73.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"64.4","ciUpperLimit":"80.9","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-1","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"64.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"37.8","ciUpperLimit":"79.3","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-2","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"84.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"71.1","ciUpperLimit":"92.1","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"groupDescription":"DENV-3","nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"58.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"18.5","ciUpperLimit":"78.5","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"79.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"59.1","ciUpperLimit":"89.9","estimateComment":"VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Hospitalization Due to Virologically Confirmed Dengue Fever Induced by Any Dengue Serotype for Parts 4 And 5 Combined","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. VE was assessed using the number of cases requiring hospitalization due to virologically-confirmed dengue fever.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 5 (Month 25b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2981"},{"groupId":"OG001","value":"5966"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"90.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"78.8","ciUpperLimit":"95.8","estimateComment":"VE and two-sided 95% CIs are estimated from a Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"VE of a TDV Booster Dose in Preventing Virologically Confirmed Severe Dengue Fever Induced by Any Dengue Serotype for Parts 4 And 5 Combined","description":"VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific RT-PCR. Severe cases were determined by Adjudication Committee. VE was assessed using the number of severe cases due to virologically-confirmed dengue fever.","populationDescription":"The PPS-B included all participants in the FAS-B who had no major protocol violations. The FAS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of cases","timeFrame":"From 30 days post-booster vaccination (Day 30b [Month 1b]) until the end of Part 5 (Month 25b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2981"},{"groupId":"OG001","value":"5966"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Cox Proportional Hazard Model","paramType":"VE","paramValue":"100","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-849.4","ciUpperLimit":"100.0","estimateComment":"VE and two-sided 95% CIs are estimated from a Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region."}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Solicited Local Injection Site Adverse Events (AEs) by Severity in the Safety Set-Booster-Immunogenicity Subset During Part 4","description":"Solicited local AEs at injection site are defined as pain, erythema and swelling that occurred within 7 days after each vaccination. The participant/legal guardian recorded the severity of each AE (except erythema and swelling) according to the diary card instruction as none, mild, moderate, or severe. Severity grades for erythema and swelling were derived from the recorded diameters. Percentages were rounded off to the nearest single decimal place.","populationDescription":"Safety Set-Booster-Immunogenicity Subset included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo) in the safety subset. Number analyzed is the number of participants with data available for analyses for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 1b through 7b after booster vaccination in Part 4","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"600"},{"groupId":"OG001","value":"1200"}]}],"classes":[{"title":"Pain: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"595"},{"groupId":"OG001","value":"1182"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.1"},{"groupId":"OG001","value":"20.1"}]}]},{"title":"Pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"595"},{"groupId":"OG001","value":"1182"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9"},{"groupId":"OG001","value":"4.6"}]}]},{"title":"Pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"595"},{"groupId":"OG001","value":"1182"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7"},{"groupId":"OG001","value":"1.2"}]}]},{"title":"Erythema: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"592"},{"groupId":"OG001","value":"1174"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2"},{"groupId":"OG001","value":"1.6"}]}]},{"title":"Erythema: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"592"},{"groupId":"OG001","value":"1174"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Erythema: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"592"},{"groupId":"OG001","value":"1174"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Swelling: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"590"},{"groupId":"OG001","value":"1173"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"1.0"}]}]},{"title":"Swelling: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"590"},{"groupId":"OG001","value":"1173"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Swelling: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"590"},{"groupId":"OG001","value":"1173"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity in the Safety Set-Booster-Immunogenicity Subset During Part 4","description":"Solicited systemic AEs are defined as fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination. The participant/legal guardian recorded the severity of each AE (except fever) according to the diary card instruction as none, mild, moderate, or severe. Severity grades for fever were derived from the recorded body temperature measurements and presented using the proposed temperature increments published by the Brighton Collaboration. Percentages were rounded off to the nearest single decimal place except the data point where rounding-up may lead to data misinterpretation.","populationDescription":"Safety Set-Booster-Immunogenicity Subset included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo) in the safety subset. Number analyzed is the number of participants with data available for analyses for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 1b through 14b after booster vaccination in Part 4","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"600"},{"groupId":"OG001","value":"1200"}]}],"classes":[{"title":"Headache: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"594"},{"groupId":"OG001","value":"1184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.6"},{"groupId":"OG001","value":"12.3"}]}]},{"title":"Headache: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"594"},{"groupId":"OG001","value":"1184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.7"},{"groupId":"OG001","value":"3.7"}]}]},{"title":"Headache: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"594"},{"groupId":"OG001","value":"1184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"1.1"}]}]},{"title":"Asthenia: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"594"},{"groupId":"OG001","value":"1184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.1"},{"groupId":"OG001","value":"7.2"}]}]},{"title":"Asthenia: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"594"},{"groupId":"OG001","value":"1184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"2.4"}]}]},{"title":"Asthenia: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"594"},{"groupId":"OG001","value":"1184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3"},{"groupId":"OG001","value":"0.7"}]}]},{"title":"Malaise: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"593"},{"groupId":"OG001","value":"1184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.6"},{"groupId":"OG001","value":"8.6"}]}]},{"title":"Malaise: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"593"},{"groupId":"OG001","value":"1184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"2.6"}]}]},{"title":"Malaise: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"593"},{"groupId":"OG001","value":"1184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0.7"}]}]},{"title":"Myalgia: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"593"},{"groupId":"OG001","value":"1181"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.9"},{"groupId":"OG001","value":"11.7"}]}]},{"title":"Myalgia: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"593"},{"groupId":"OG001","value":"1181"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"},{"groupId":"OG001","value":"3.6"}]}]},{"title":"Myalgia: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"593"},{"groupId":"OG001","value":"1181"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0"},{"groupId":"OG001","value":"0.8"}]}]},{"title":"Fever: 38.0-<38.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"584"},{"groupId":"OG001","value":"1146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0"},{"groupId":"OG001","value":"1.8"}]}]},{"title":"Fever: 38.5-<39.0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"584"},{"groupId":"OG001","value":"1146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"1.0"}]}]},{"title":"Fever: 39.0-<39.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"584"},{"groupId":"OG001","value":"1146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2"},{"groupId":"OG001","value":"0.2"}]}]},{"title":"Fever: 39.5-<40.0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"584"},{"groupId":"OG001","value":"1146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.3"}]}]},{"title":"Fever: 40.0-<40.5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"584"},{"groupId":"OG001","value":"1146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Fever: 40.5-<41.0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"584"},{"groupId":"OG001","value":"1146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.0873"}]}]},{"title":"Fever: >=41.0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"584"},{"groupId":"OG001","value":"1146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Any Unsolicited Adverse Events (AEs) in the Safety Set-Booster-Immunogenicity Subset During Part 4","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study. Percentages were rounded off to the nearest single decimal place.","populationDescription":"Safety Set-Booster-Immunogenicity Subset included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo) in the safety subset.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 1b through 28b after booster vaccination in Part 4","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"600"},{"groupId":"OG001","value":"1200"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"},{"groupId":"OG001","value":"1.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Serious Adverse Events (SAEs) During Parts 4 and 5","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. Percentages were rounded off to the nearest single decimal place. In the category 'Part 4 and 5 combined' participants are counted only once even if they experienced events in both Part 4 and Part 5 in order to yield total of unique participants who had SAEs.","populationDescription":"Safety Set-Booster (SS-B) included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo). Number analyzed is the number of participants at risk at the start of the specified analysis period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From Day 1b until the end of Part 4 (Month 13b) and Part 5 (Month 25b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2985"},{"groupId":"OG001","value":"5990"}]}],"classes":[{"title":"Part 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2985"},{"groupId":"OG001","value":"5990"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.2"},{"groupId":"OG001","value":"2.7"}]}]},{"title":"Part 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2939"},{"groupId":"OG001","value":"5889"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"1.9"}]}]},{"title":"Parts 4 and 5 Combined","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2985"},{"groupId":"OG001","value":"5990"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.4"},{"groupId":"OG001","value":"4.4"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Fatal SAEs and SAEs Related to Study Drug During Parts 4 and 5","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation. In the category 'Part 4 and 5 combined' participants are counted only once even if they experienced events in both Part 4 and Part 5 in order to yield total of unique participants who had SAEs.","populationDescription":"SS-B included all participants 4 to 11 years of age at the time of randomization in the trial (Day 1 \\[Month 0\\]) who were included in the PPS and who received the booster dose of trial vaccine (TDV or placebo). Number analyzed is the number of participants at risk at the start of the specified analysis period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From Day 1b until the end of Part 4 (Month 13b) and Part 5 (Month 25b)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2985"},{"groupId":"OG001","value":"5990"}]}],"classes":[{"title":"Part 4: Fatal SAEs","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2985"},{"groupId":"OG001","value":"5990"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0335"},{"groupId":"OG001","value":"0.0501"}]}]},{"title":"Part 4: SAEs Related to Study Drug","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2985"},{"groupId":"OG001","value":"5990"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Part 5: Fatal SAEs","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2939"},{"groupId":"OG001","value":"5889"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.0509"}]}]},{"title":"Part 5: SAEs Related to Study Drug","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2939"},{"groupId":"OG001","value":"5889"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Parts 4&5 Combined: Fatal SAEs","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2985"},{"groupId":"OG001","value":"5990"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0335"},{"groupId":"OG001","value":"0.1"}]}]},{"title":"Parts 4&5 Combined: SAEs Related to Study Drug","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2985"},{"groupId":"OG001","value":"5990"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Seropositivity Rate for Each of The 4 Dengue Serotypes During Parts 4 and 5","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The four DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation.","populationDescription":"Per-Protocol Set for Immunogenicity-Booster (PPSI-B):all participants in Full Analysis Set for Immunogenicity-Booster (FASI-B) who had no major protocol violations. FASI-B: all participants from FAS-B who were included in booster immunogenicity subset \\& for whom there is valid pre-booster measurement \\& at least 1 valid post-booster measurement for immunogenicity assessments. Number analyzed: participants with data available for analyses for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Pre-booster Vaccination on Day 1b (Month 0b) and post-booster vaccination on Day 30b (Month 1b), Day 180b (Month 6b), Day 395b (Month 13b) and Day 760b (Month 25b) in Parts 4 and 5","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"classes":[{"title":"Day 1b: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.2"},{"groupId":"OG001","value":"94.4"}]}]},{"title":"Day 1b: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.5"},{"groupId":"OG001","value":"99.2"}]}]},{"title":"Day 1b: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.0"},{"groupId":"OG001","value":"97.0"}]}]},{"title":"Day 1b: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.0"},{"groupId":"OG001","value":"93.4"}]}]},{"title":"Month 1b: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"542"},{"groupId":"OG001","value":"1075"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.6"},{"groupId":"OG001","value":"99.907"}]}]},{"title":"Month 1b: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"542"},{"groupId":"OG001","value":"1075"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.5"},{"groupId":"OG001","value":"99.907"}]}]},{"title":"Month 1b: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"542"},{"groupId":"OG001","value":"1075"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.9"},{"groupId":"OG001","value":"100.0"}]}]},{"title":"Month 1b: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"542"},{"groupId":"OG001","value":"1075"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.2"},{"groupId":"OG001","value":"99.7"}]}]},{"title":"Month 6b: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"1127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.8"},{"groupId":"OG001","value":"99.7"}]}]},{"title":"Month 6b: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"1126"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.8"},{"groupId":"OG001","value":"99.8"}]}]},{"title":"Month 6b: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"1127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.0"},{"groupId":"OG001","value":"99.6"}]}]},{"title":"Month 6b: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"1127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.3"},{"groupId":"OG001","value":"99.7"}]}]},{"title":"Month 13b: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"1122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.5"},{"groupId":"OG001","value":"99.911"}]}]},{"title":"Month 13b: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"1122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.4"},{"groupId":"OG001","value":"99.5"}]}]},{"title":"Month 13b: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"1122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.9"},{"groupId":"OG001","value":"100.0"}]}]},{"title":"Month 13b: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"1122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.4"},{"groupId":"OG001","value":"99.8"}]}]},{"title":"Month 25b: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"1103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.2"},{"groupId":"OG001","value":"99.6"}]}]},{"title":"Month 25b: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"1103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.6"},{"groupId":"OG001","value":"99.8"}]}]},{"title":"Month 25b: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"1102"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.7"},{"groupId":"OG001","value":"99.909"}]}]},{"title":"Month 25b: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"1103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76.3"},{"groupId":"OG001","value":"99.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Seropositivity Rate for Multiple Dengue Serotypes During Parts 4 and 5","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for any one (monovalent), two (bivalent), three (trivalent), and four (tetravalent) dengue serotypes, as well as at least bivalent (seropositive for ≥2 dengue serotypes) and at least trivalent (seropositive for ≥3 dengue serotypes), is derived from the titers of dengue-neutralizing antibodies. Seropositive response is defined as a reciprocal neutralizing titer ≥ 10. The four DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Percentages were rounded off to the nearest single decimal place except the data points where rounding-up may lead to data misinterpretation.","populationDescription":"PPSI-B: all participants in FASI-B who had no major protocol violations. FASI-B: all participants from FAS-B who were included in booster immunogenicity subset \\& for whom there is valid pre-booster measurement \\& at least 1 valid post-booster measurement for immunogenicity assessments. Number analyzed: number of participants with data available for analyses for specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Pre-booster vaccination on Day 1b (Month 0b) and post-booster vaccination on Day 30b (Month 1b), Day 180b (Month 6b), Day 395b (Month 13b) and Day 760b (Month 25b) in Parts 4 and 5","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"classes":[{"title":"Day 1b: Monovalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"1.3"}]}]},{"title":"Day 1b: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"3.7"}]}]},{"title":"Day 1b: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3"},{"groupId":"OG001","value":"4.6"}]}]},{"title":"Day 1b: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.5"},{"groupId":"OG001","value":"90.4"}]}]},{"title":"Day 1b: At Least Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.8"},{"groupId":"OG001","value":"98.7"}]}]},{"title":"Day 1b: At Least Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.8"},{"groupId":"OG001","value":"95.0"}]}]},{"title":"Month 1b: Monovalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"542"},{"groupId":"OG001","value":"1075"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.6"},{"groupId":"OG001","value":"0"}]}]},{"title":"Month 1b: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"542"},{"groupId":"OG001","value":"1075"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Month 1b: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"542"},{"groupId":"OG001","value":"1075"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.7"},{"groupId":"OG001","value":"0.5"}]}]},{"title":"Month 1b: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"542"},{"groupId":"OG001","value":"1075"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.6"},{"groupId":"OG001","value":"99.5"}]}]},{"title":"Month 1b:At Least Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"542"},{"groupId":"OG001","value":"1075"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.3"},{"groupId":"OG001","value":"100.0"}]}]},{"title":"Month 1b:At Least Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"542"},{"groupId":"OG001","value":"1075"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.3"},{"groupId":"OG001","value":"100.0"}]}]},{"title":"Month 6b:Monovalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"1127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.8"},{"groupId":"OG001","value":"0.0887"}]}]},{"title":"Month 6b: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"1127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"0.0887"}]}]},{"title":"Month 6b: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"1127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.2"},{"groupId":"OG001","value":"0.6"}]}]},{"title":"Month 6b: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"1126"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.6"},{"groupId":"OG001","value":"99.2"}]}]},{"title":"Month 6b:At Least Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"1127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.3"},{"groupId":"OG001","value":"99.911"}]}]},{"title":"Month 6b:At Least Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"1127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.8"},{"groupId":"OG001","value":"99.8"}]}]},{"title":"Month 13b: Monovalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"1122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.6"},{"groupId":"OG001","value":"0"}]}]},{"title":"Month 13b: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"1122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Month 13b: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"1122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.7"},{"groupId":"OG001","value":"0.8"}]}]},{"title":"Month 13b: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"1122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.1"},{"groupId":"OG001","value":"99.2"}]}]},{"title":"Month 13b: At Least Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"1122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.9"},{"groupId":"OG001","value":"100.0"}]}]},{"title":"Month 13b: At Least Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"1122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.7"},{"groupId":"OG001","value":"100.0"}]}]},{"title":"Month 25b: Monovalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"1103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4"},{"groupId":"OG001","value":"0"}]}]},{"title":"Month 25b: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"1103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"},{"groupId":"OG001","value":"0.0907"}]}]},{"title":"Month 25b: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"1103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"},{"groupId":"OG001","value":"0.4"}]}]},{"title":"Month 25b: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"1102"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.5"},{"groupId":"OG001","value":"99.5"}]}]},{"title":"Month 25b: At Least Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"1103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.9"},{"groupId":"OG001","value":"99.909"}]}]},{"title":"Month 25b: At Least Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"1103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76.1"},{"groupId":"OG001","value":"99.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the Four Dengue Serotypes During Parts 4 And 5","description":"GMTs of neutralizing antibodies were measured via MNT50. The four DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.","populationDescription":"PPSI-B: all participants in FASI-B who had no major protocol violations. FASI-B: all participants from FAS-B who were included in booster immunogenicity subset \\& for whom there is valid pre-booster measurement \\& at least 1 valid post-booster measurement for immunogenicity assessments. Number analyzed: number of participants with data available for analyses for specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titres","timeFrame":"Pre-booster Vaccination on Day 1b (Month 0b) and post-booster vaccination on Day 30b (Month 1b), Day 180b (Month 6b), Day 395b (Month 13b) and Day 760b (Month 25b) in Parts 4 and 5","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"classes":[{"title":"Day 1b: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"172.7","lowerLimit":"137.8","upperLimit":"216.5"},{"groupId":"OG001","value":"374.7","lowerLimit":"332.7","upperLimit":"422.1"}]}]},{"title":"Day 1b: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"164.5","lowerLimit":"133.2","upperLimit":"203.2"},{"groupId":"OG001","value":"609.4","lowerLimit":"558.6","upperLimit":"664.7"}]}]},{"title":"Day 1b: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"129.4","lowerLimit":"105.0","upperLimit":"159.4"},{"groupId":"OG001","value":"305.2","lowerLimit":"274.6","upperLimit":"339.3"}]}]},{"title":"Day 1b: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"1186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.5","lowerLimit":"67.8","upperLimit":"98.1"},{"groupId":"OG001","value":"172.9","lowerLimit":"156.1","upperLimit":"191.4"}]}]},{"title":"Month 1b: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"542"},{"groupId":"OG001","value":"1075"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"179.8","lowerLimit":"142.4","upperLimit":"227.0"},{"groupId":"OG001","value":"1493.8","lowerLimit":"1383.2","upperLimit":"1613.3"}]}]},{"title":"Month 1b: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"542"},{"groupId":"OG001","value":"1075"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"174.8","lowerLimit":"140.5","upperLimit":"217.6"},{"groupId":"OG001","value":"1611.5","lowerLimit":"1492.1","upperLimit":"1740.4"}]}]},{"title":"Month 1b: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"542"},{"groupId":"OG001","value":"1075"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"159.9","lowerLimit":"128.4","upperLimit":"199.0"},{"groupId":"OG001","value":"1546.6","lowerLimit":"1450.0","upperLimit":"1649.6"}]}]},{"title":"Month 1b: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"542"},{"groupId":"OG001","value":"1075"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","lowerLimit":"72.0","upperLimit":"105.9"},{"groupId":"OG001","value":"793.8","lowerLimit":"742.5","upperLimit":"848.7"}]}]},{"title":"Month 6b: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"1127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"191.5","lowerLimit":"152.2","upperLimit":"241.0"},{"groupId":"OG001","value":"1000.9","lowerLimit":"916.8","upperLimit":"1092.7"}]}]},{"title":"Month 6b: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"1127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"208.0","lowerLimit":"167.6","upperLimit":"258.0"},{"groupId":"OG001","value":"1167.2","lowerLimit":"1080.8","upperLimit":"1260.5"}]}]},{"title":"Month 6b: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"1127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"156.0","lowerLimit":"126.1","upperLimit":"192.9"},{"groupId":"OG001","value":"851.0","lowerLimit":"788.9","upperLimit":"917.9"}]}]},{"title":"Month 6b: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"1127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.4","lowerLimit":"71.9","upperLimit":"103.9"},{"groupId":"OG001","value":"457.6","lowerLimit":"427.4","upperLimit":"490.0"}]}]},{"title":"Month 13b: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"1122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"259.3","lowerLimit":"204.8","upperLimit":"328.4"},{"groupId":"OG001","value":"949.1","lowerLimit":"862.2","upperLimit":"1044.7"}]}]},{"title":"Month 13b: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"1122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"248.9","lowerLimit":"199.4","upperLimit":"310.6"},{"groupId":"OG001","value":"1003.2","lowerLimit":"920.1","upperLimit":"1093.9"}]}]},{"title":"Month 13b: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"1122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"199.1","lowerLimit":"159.9","upperLimit":"248.0"},{"groupId":"OG001","value":"804.1","lowerLimit":"739.2","upperLimit":"874.8"}]}]},{"title":"Month 13b: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"1122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"115.0","lowerLimit":"94.4","upperLimit":"140.0"},{"groupId":"OG001","value":"433.1","lowerLimit":"401.2","upperLimit":"467.6"}]}]},{"title":"Month 25b: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"1103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"293.8","lowerLimit":"233.1","upperLimit":"370.3"},{"groupId":"OG001","value":"865.6","lowerLimit":"782.7","upperLimit":"957.2"}]}]},{"title":"Month 25b: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"1103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"278.5","lowerLimit":"224.3","upperLimit":"345.8"},{"groupId":"OG001","value":"951.6","lowerLimit":"873.0","upperLimit":"1037.2"}]}]},{"title":"Month 25b: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"1102"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"229.7","lowerLimit":"185.5","upperLimit":"284.3"},{"groupId":"OG001","value":"688.3","lowerLimit":"632.2","upperLimit":"749.3"}]}]},{"title":"Month 25b: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"1103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"129.2","lowerLimit":"106.8","upperLimit":"156.3"},{"groupId":"OG001","value":"387.9","lowerLimit":"358.6","upperLimit":"419.6"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Geometric Mean Ratio (GMR) of Neutralizing Antibodies for Each Dengue Serotype","description":"The GMR is the geometric mean of the ratio of the two visits being compared.","populationDescription":"PPSI-B: all participants in FASI-B who had no major protocol violations. FASI-B: all participants from FAS-B who were included in booster immunogenicity subset \\& for whom there is valid pre-booster measurement \\& at least 1 valid post-booster measurement for immunogenicity assessments. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analyses for specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"unitless ratio","timeFrame":"Pre-booster Vaccination on Day 1b (Month 0b) versus post-booster vaccination on Day 30b (Month 1b) in Part 4","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"396"},{"groupId":"OG001","value":"1067"}]}],"classes":[{"title":"DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"1016"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.8","upperLimit":"1.0"},{"groupId":"OG001","value":"3.1","lowerLimit":"2.8","upperLimit":"3.4"}]}]},{"title":"DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"396"},{"groupId":"OG001","value":"1067"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.9","upperLimit":"1.0"},{"groupId":"OG001","value":"2.4","lowerLimit":"2.3","upperLimit":"2.6"}]}]},{"title":"DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"1042"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"1.0","upperLimit":"1.2"},{"groupId":"OG001","value":"4.3","lowerLimit":"3.9","upperLimit":"4.7"}]}]},{"title":"DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"365"},{"groupId":"OG001","value":"1008"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.9","upperLimit":"1.0"},{"groupId":"OG001","value":"3.5","lowerLimit":"3.2","upperLimit":"3.9"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"GMR of Neutralizing Antibodies for Each Dengue Serotype","description":"The GMR is the geometric mean of the ratio of the two visits being compared.","populationDescription":"PPSI-B: all participants in FASI-B who had no major protocol violations. FASI-B: all participants from FAS-B who were included in booster immunogenicity subset \\& for whom there is valid pre-booster measurement \\& at least 1 valid post-booster measurement for immunogenicity assessments. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analyses for specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"unitless ratio","timeFrame":"Pre-booster Vaccination on Day 1b (Month 0b) versus post-booster vaccination on Day 180b (Month 6b) in Part 4","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"408"},{"groupId":"OG001","value":"1120"}]}],"classes":[{"title":"DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"396"},{"groupId":"OG001","value":"1064"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.9","upperLimit":"1.1"},{"groupId":"OG001","value":"2.2","lowerLimit":"2.0","upperLimit":"2.4"}]}]},{"title":"DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"408"},{"groupId":"OG001","value":"1120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"1.0","upperLimit":"1.3"},{"groupId":"OG001","value":"1.8","lowerLimit":"1.7","upperLimit":"2.0"}]}]},{"title":"DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"1094"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.9","upperLimit":"1.1"},{"groupId":"OG001","value":"2.5","lowerLimit":"2.3","upperLimit":"2.7"}]}]},{"title":"DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"1052"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.8","upperLimit":"1.0"},{"groupId":"OG001","value":"2.1","lowerLimit":"2.0","upperLimit":"2.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"GMR of Neutralizing Antibodies for Each Dengue Serotype","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared.","populationDescription":"PPSI-B: all participants in FASI-B who had no major protocol violations. FASI-B: all participants from FAS-B who were included in booster immunogenicity subset \\& for whom there is valid pre-booster measurement \\& at least 1 valid post-booster measurement for immunogenicity assessments. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analyses for specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"unitless ratio","timeFrame":"Pre-booster Vaccination on Day 1b (Month 0b) versus post-booster vaccination on Day 395b (Month 13b) in Part 4","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"408"},{"groupId":"OG001","value":"1114"}]}],"classes":[{"title":"DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"395"},{"groupId":"OG001","value":"1060"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"1.1","upperLimit":"1.5"},{"groupId":"OG001","value":"2.1","lowerLimit":"1.9","upperLimit":"2.3"}]}]},{"title":"DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"408"},{"groupId":"OG001","value":"1114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"1.1","upperLimit":"1.5"},{"groupId":"OG001","value":"1.6","lowerLimit":"1.5","upperLimit":"1.7"}]}]},{"title":"DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"1088"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"1.1","upperLimit":"1.5"},{"groupId":"OG001","value":"2.4","lowerLimit":"2.2","upperLimit":"2.6"}]}]},{"title":"DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"1047"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"1.1","upperLimit":"1.4"},{"groupId":"OG001","value":"2.0","lowerLimit":"1.9","upperLimit":"2.2"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"GMR of Neutralizing Antibodies for Each Dengue Serotype","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared.","populationDescription":"PPSI-B: all participants in FASI-B who had no major protocol violations. FASI-B: all participants from FAS-B who were included in booster immunogenicity subset \\& for whom there is valid pre-booster measurement \\& at least 1 valid post-booster measurement for immunogenicity assessments. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analyses for specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"unitless ratio","timeFrame":"Pre-booster Vaccination on Day 1b (Month 0b) versus post-booster vaccination on Day 720b (Month 25b) in Part 5","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."},{"id":"OG001","title":"TDV 0.5 mL","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"398"},{"groupId":"OG001","value":"1095"}]}],"classes":[{"title":"DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"384"},{"groupId":"OG001","value":"1043"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"1.2","upperLimit":"1.5"},{"groupId":"OG001","value":"2.0","lowerLimit":"1.9","upperLimit":"2.2"}]}]},{"title":"DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"398"},{"groupId":"OG001","value":"1095"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"1.1","upperLimit":"1.5"},{"groupId":"OG001","value":"1.6","lowerLimit":"1.5","upperLimit":"1.7"}]}]},{"title":"DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"1068"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"1.2","upperLimit":"1.6"},{"groupId":"OG001","value":"2.1","lowerLimit":"1.9","upperLimit":"2.3"}]}]},{"title":"DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"367"},{"groupId":"OG001","value":"1028"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"1.1","upperLimit":"1.5"},{"groupId":"OG001","value":"1.9","lowerLimit":"1.8","upperLimit":"2.1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Part 1+ Part 2 combined: Deaths and SAEs from Day1 until end of Part 2(approx.21 months); Other AEs up to 28 days post first/second vaccination- i.e. only Part1; Part3: Deaths and SAEs during Part3(approx.3 years); no Other AEs collected during Part 3; Part 4+ Part 5 combined: Deaths and SAEs from booster vaccination (Day 1b) until end of Part 5 [approx. 25 months]; Other AEs up to 28 days post booster vaccination- i.e. only Part 4).","description":"As pre-specified in protocol, AEs are reported separately for Placebo and TDV arms of each Part. For Part 1-3: Safety Set. For Part 4-5: Safety Set-Booster.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Participants received placebo-matching TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study. Participants eligible for Booster Phase received placebo matching TDV, SC injection on Day 1b (Month 0b) in Part 4 of the study based on the randomization code applied in Part 1 of the study.","deathsNumAffected":8,"deathsNumAtRisk":6687,"seriousNumAffected":256,"seriousNumAtRisk":6687,"otherNumAffected":527,"otherNumAtRisk":6687},{"id":"EG001","title":"TDV (Part 1)","description":"Participants received TDV, 0.5 mL, SC injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study.","deathsNumAffected":22,"deathsNumAtRisk":13380,"seriousNumAffected":414,"seriousNumAtRisk":13380,"otherNumAffected":1260,"otherNumAtRisk":13380},{"id":"EG002","title":"Placebo (Part 2)","description":"Participants went through extended follow-up period for six months up to Month 21 in Part 2 of the study.","deathsNumAffected":7,"deathsNumAtRisk":6519,"seriousNumAffected":82,"seriousNumAtRisk":6519,"otherNumAffected":0,"otherNumAtRisk":6519},{"id":"EG003","title":"TDV (Part 2)","description":"Participants went through extended follow-up period for six months up to Month 21 in Part 2 of the study.","deathsNumAffected":18,"deathsNumAtRisk":13033,"seriousNumAffected":152,"seriousNumAtRisk":13033,"otherNumAffected":0,"otherNumAtRisk":13033},{"id":"EG004","title":"Placebo (Part 3)","description":"Participants went through long-term follow-up (3 years) to evaluate the safety.","deathsNumAffected":7,"deathsNumAtRisk":6487,"seriousNumAffected":397,"seriousNumAtRisk":6487,"otherNumAffected":0,"otherNumAtRisk":6487},{"id":"EG005","title":"TDV (Part 3)","description":"Participants eligible for Booster Phase received placebo matching TDV, SC injection, based on the randomization on Day 1 (Month 0) in Part 4 of the study.","deathsNumAffected":17,"deathsNumAtRisk":12961,"seriousNumAffected":666,"seriousNumAtRisk":12961,"otherNumAffected":0,"otherNumAtRisk":12961},{"id":"EG006","title":"Placebo (Part 4)","description":"Participants eligible for Booster Phase received placebo matching TDV, SC injection, based on the randomization on Day 1 (Month 0)in Part 4 of the study.","deathsNumAffected":1,"deathsNumAtRisk":2985,"seriousNumAffected":126,"seriousNumAtRisk":2985,"otherNumAffected":149,"otherNumAtRisk":2985},{"id":"EG007","title":"TDV (Part 4)","description":"Participants eligible for Booster Phase received TDV, SC injection, based on the randomization on Day 1 (Month 0) in Part 4 of the study.","deathsNumAffected":6,"deathsNumAtRisk":5990,"seriousNumAffected":161,"seriousNumAtRisk":5990,"otherNumAffected":409,"otherNumAtRisk":5990},{"id":"EG008","title":"Placebo (Part 5)","description":"Participants went through extended follow-up period for 1 year up to Month 25b in Part 5 of the study.","deathsNumAffected":0,"deathsNumAtRisk":2939,"seriousNumAffected":73,"seriousNumAtRisk":2939,"otherNumAffected":0,"otherNumAtRisk":2939},{"id":"EG009","title":"TDV (Part 5)","description":"Participants went through extended follow-up period for 1 year up to Month 25b in Part 5 of the study.","deathsNumAffected":3,"deathsNumAtRisk":5889,"seriousNumAffected":109,"seriousNumAtRisk":5889,"otherNumAffected":0,"otherNumAtRisk":5889}],"seriousEvents":[{"term":"Abdominal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abdominal injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":4,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":3,"numAtRisk":6487},{"groupId":"EG005","numAffected":4,"numAtRisk":12961},{"groupId":"EG006","numAffected":2,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abnormal uterine bleeding","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abnormal weight gain","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abortion","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abortion complete","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abortion incomplete","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abortion induced","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abortion infected","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abortion missed","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":7,"numAtRisk":6487},{"groupId":"EG005","numAffected":6,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":3,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abortion spontaneous incomplete","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abortion threatened","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abscess jaw","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abscess limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":5,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":7,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":2,"numAtRisk":5889}]},{"term":"Abscess neck","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abscess of external ear","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Abscess soft tissue","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Acarodermatitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Accident at work","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Accidental exposure to product by child","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Acid peptic disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Acute disseminated encephalomyelitis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Acute psychosis","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Acute sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":2,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Adenocarcinoma of colon","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Adenoidal hypertrophy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Adjustment disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Adjustment disorder with depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Aggression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Alcohol poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Allergy to arthropod bite","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Alveolar rhabdomyosarcoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Amaurosis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Amniotic cavity infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Amoebiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Amoebic dysentery","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":6,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Anaemia of pregnancy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Anaphylactic shock","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Anembryonic gestation","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Animal bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":6687},{"groupId":"EG001","numAffected":8,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":3,"numAtRisk":6487},{"groupId":"EG005","numAffected":10,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":2,"numAtRisk":5990},{"groupId":"EG008","numAffected":2,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Antisocial behaviour","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Anxiety disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Aortic valve incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Aphthous ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Appendiceal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":6687},{"groupId":"EG001","numAffected":30,"numAtRisk":13380},{"groupId":"EG002","numAffected":6,"numAtRisk":6519},{"groupId":"EG003","numAffected":14,"numAtRisk":13033},{"groupId":"EG004","numAffected":27,"numAtRisk":6487},{"groupId":"EG005","numAffected":60,"numAtRisk":12961},{"groupId":"EG006","numAffected":5,"numAtRisk":2985},{"groupId":"EG007","numAffected":7,"numAtRisk":5990},{"groupId":"EG008","numAffected":4,"numAtRisk":2939},{"groupId":"EG009","numAffected":12,"numAtRisk":5889}]},{"term":"Appendicitis perforated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":3,"numAtRisk":13033},{"groupId":"EG004","numAffected":6,"numAtRisk":6487},{"groupId":"EG005","numAffected":7,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":3,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":2,"numAtRisk":5889}]},{"term":"Aqueductal stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Arboviral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Arteriovenous malformation","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Arthritis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Arthritis reactive","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Arthropod bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Arthropod sting","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Ascariasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Asphyxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":7,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":7,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":5,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":3,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":2,"numAtRisk":5889}]},{"term":"Asthmatic crisis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Atrial septal defect","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Atypical pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Autoimmune hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Avulsion fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Back injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Bacterial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Bacterial sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Bacterial vaginosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Bacteriuria","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Balanoposthitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Bartholin's abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Behaviour disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Behcet's syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Bell's palsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Benign hydatidiform mole","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Benign ovarian tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Bipolar I disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Bipolar disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Blindness traumatic","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Blood loss anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Brain hypoxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Breast abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Breast cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":4,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Bronchitis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Bullous impetigo","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Burkholderia pseudomallei infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Burn infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Burns second degree","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":24,"numAtRisk":6487},{"groupId":"EG005","numAffected":69,"numAtRisk":12961},{"groupId":"EG006","numAffected":39,"numAtRisk":2985},{"groupId":"EG007","numAffected":65,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":3,"numAtRisk":6487},{"groupId":"EG005","numAffected":7,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Calculus urinary","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Carcinoma in situ","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":10,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":3,"numAtRisk":13033},{"groupId":"EG004","numAffected":7,"numAtRisk":6487},{"groupId":"EG005","numAffected":15,"numAtRisk":12961},{"groupId":"EG006","numAffected":2,"numAtRisk":2985},{"groupId":"EG007","numAffected":3,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cellulitis orbital","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cephalo-pelvic disproportion","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cerebellar infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cerebral arteriovenous malformation haemorrhagic","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cerebral venous thrombosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cerebrovascular arteriovenous malformation","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Chemical burn of oral cavity","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Chest injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Chikungunya virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cholangitis sclerosing","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cholera","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Clavicle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":4,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Complicated appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":6,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":7,"numAtRisk":6487},{"groupId":"EG005","numAffected":12,"numAtRisk":12961},{"groupId":"EG006","numAffected":4,"numAtRisk":2985},{"groupId":"EG007","numAffected":2,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":2,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Congenital cystic kidney disease","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Conjunctivitis allergic","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":3,"numAtRisk":6487},{"groupId":"EG005","numAffected":5,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Corneal opacity","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Coronavirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Costochondritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Craniofacial fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Croup infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cryptorchism","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cushing's syndrome","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cutaneous T-cell lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Deficiency anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":3,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Dengue fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":52,"numAtRisk":6687},{"groupId":"EG001","numAffected":13,"numAtRisk":13380},{"groupId":"EG002","numAffected":10,"numAtRisk":6519},{"groupId":"EG003","numAffected":9,"numAtRisk":13033},{"groupId":"EG004","numAffected":83,"numAtRisk":6487},{"groupId":"EG005","numAffected":56,"numAtRisk":12961},{"groupId":"EG006","numAffected":32,"numAtRisk":2985},{"groupId":"EG007","numAffected":7,"numAtRisk":5990},{"groupId":"EG008","numAffected":17,"numAtRisk":2939},{"groupId":"EG009","numAffected":9,"numAtRisk":5889}]},{"term":"Dengue haemorrhagic fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":6687},{"groupId":"EG001","numAffected":4,"numAtRisk":13380},{"groupId":"EG002","numAffected":6,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":12,"numAtRisk":6487},{"groupId":"EG005","numAffected":9,"numAtRisk":12961},{"groupId":"EG006","numAffected":4,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":3,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":7,"numAtRisk":12961},{"groupId":"EG006","numAffected":2,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Dermatitis infected","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Dermoid cyst","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Desmoplastic small round cell tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Device extrusion","organSystem":"Product Issues","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Device malfunction","organSystem":"Product Issues","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Diarrhoea infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Diplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Disruptive mood dysregulation disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Disseminated intravascular coagulation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Disseminated tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Drowning","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Drug abuse","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Dysentery","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Eclampsia","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Electric injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Electric shock","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Electrical burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"End stage renal disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Enteritis infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Ependymoma malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Epididymitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Epidural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Epiphyseal injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Epiphysiolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Erythema annulare","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Erythema infectiosum","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Escherichia sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Escherichia urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Exostosis of jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Exposure to communicable disease","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Extradural abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Extradural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Extremity contracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Extremity necrosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Eye infection gonococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Eye injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Eyelid injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Face injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Faecaloma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":4,"numAtRisk":12961},{"groupId":"EG006","numAffected":3,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"False labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"False positive investigation result","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Familial periodic paralysis","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Febrile convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":4,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Fibroadenoma of breast","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Fibromyalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Fibula fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Focal peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Folliculitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Food allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Food poisoning","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":3,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":2,"numAtRisk":2939},{"groupId":"EG009","numAffected":2,"numAtRisk":5889}]},{"term":"Forearm fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":8,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":9,"numAtRisk":12961},{"groupId":"EG006","numAffected":4,"numAtRisk":2985},{"groupId":"EG007","numAffected":3,"numAtRisk":5990},{"groupId":"EG008","numAffected":2,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Foreign body in gastrointestinal tract","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Fractured coccyx","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":6,"numAtRisk":13380},{"groupId":"EG002","numAffected":3,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":3,"numAtRisk":6487},{"groupId":"EG005","numAffected":6,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Gastritis erosive","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Gastritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":6687},{"groupId":"EG001","numAffected":29,"numAtRisk":13380},{"groupId":"EG002","numAffected":2,"numAtRisk":6519},{"groupId":"EG003","numAffected":7,"numAtRisk":13033},{"groupId":"EG004","numAffected":11,"numAtRisk":6487},{"groupId":"EG005","numAffected":18,"numAtRisk":12961},{"groupId":"EG006","numAffected":2,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":4,"numAtRisk":5889}]},{"term":"Gastroenteritis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Gastroenteritis salmonella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Gastroenteritis shigella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Gastrointestinal bacterial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Gastrointestinal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Generalised tonic-clonic seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Gestational hypertension","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Giardiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Glomerulonephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Glomerulonephritis acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Glomerulonephritis chronic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Glomerulonephritis proliferative","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Glomerulonephritis rapidly progressive","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Goitre","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Greater trochanteric pain syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Groin abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Guillain-Barre syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Gun shot wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":3,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Haemophagocytic lymphohistiocytosis","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Haemorrhagic erosive gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hand fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":2,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":3,"numAtRisk":6487},{"groupId":"EG005","numAffected":5,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Hand-foot-and-mouth disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hanging","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":6687},{"groupId":"EG001","numAffected":4,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Henoch-Schonlein purpura","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hepatic rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hepatic steatosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hepatitis A","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hepatitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hepatitis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hepatosplenomegaly","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Herpes simplex encephalitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"High risk pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"High risk sexual behaviour","organSystem":"Social circumstances","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hodgkin's disease","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":6687},{"groupId":"EG001","numAffected":10,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":7,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hyperemesis gravidarum","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hyperkeratosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hypertensive nephropathy","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hypertensive urgency","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Idiopathic generalised epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"IgA nephropathy","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Ileus paralytic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Ilium fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Immune thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Impetigo","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Incarcerated umbilical hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Infected bite","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Infectious mononucleosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Infective exacerbation of asthma","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Infective myositis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Inflammatory myofibroblastic tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":6687},{"groupId":"EG001","numAffected":14,"numAtRisk":13380},{"groupId":"EG002","numAffected":5,"numAtRisk":6519},{"groupId":"EG003","numAffected":6,"numAtRisk":13033},{"groupId":"EG004","numAffected":9,"numAtRisk":6487},{"groupId":"EG005","numAffected":12,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":3,"numAtRisk":5889}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Intentional overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Intentional self-injury","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":2,"numAtRisk":5889}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Intra-abdominal fluid collection","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Irritable bowel syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Jaw fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Joint abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":2,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Joint injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Juvenile idiopathic arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Kawasaki's disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Knee deformity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Labour complication","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Large intestine polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Leptospirosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Lichen planus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Ligament injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Limb crushing injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":3,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":4,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Limb traumatic amputation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Lip injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Lipoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Liver contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Lower limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":4,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":6687},{"groupId":"EG001","numAffected":10,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":3,"numAtRisk":13033},{"groupId":"EG004","numAffected":3,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Ludwig angina","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Lupus nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Lupus pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Lymph gland infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Lymph node tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Lymphadenitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Lymphoid hyperplasia of intestine","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Major depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Malaria","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Mallory-Weiss syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Mania","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Mastoiditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Measles","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Mechanical ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Medulloblastoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Meningitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Meningitis aseptic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Meningitis tuberculous","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Mesenteric cyst","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Mesenteric lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":5,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":4,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":2,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Metabolic dysfunction-associated steatohepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Metabolic syndrome","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Mixed anxiety and depressive disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Multiple injuries","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":4,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Muscle abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Muscle fatigue","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Muscle injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Muscle strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Muscular dystrophy","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Myelopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Myopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Neck injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Nephritic syndrome","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Nephrotic syndrome","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Obesity","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Obstetric infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Obstructive sleep apnoea syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Oesophageal varices haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Open globe injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Oppositional defiant disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Optic neuritis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Orbital myositis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Orchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Organ failure","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Osteochondroma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Osteomyelitis chronic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Otitis externa","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Otitis media acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Ovarian germ cell endodermal sinus tumour stage IV","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Ovulation pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pancreatic injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Pancreatic pseudocyst","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Papillary thyroid cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Paranasal sinus abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Parasite allergy","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Parasitic gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Parotitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Patella fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pelvic abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pelvic fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pelvic inflammatory disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":2,"numAtRisk":5889}]},{"term":"Penetrating abdominal trauma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Penile adhesion","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Peptic ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Perineal injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Periorbital abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Periorbital cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Peritonsillar abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":3,"numAtRisk":13033},{"groupId":"EG004","numAffected":3,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pharyngitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Pharyngotonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Phimosis","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Physical assault","organSystem":"Social circumstances","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pilonidal disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Placental insufficiency","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":6687},{"groupId":"EG001","numAffected":10,"numAtRisk":13380},{"groupId":"EG002","numAffected":7,"numAtRisk":6519},{"groupId":"EG003","numAffected":6,"numAtRisk":13033},{"groupId":"EG004","numAffected":8,"numAtRisk":6487},{"groupId":"EG005","numAffected":20,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":2,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":3,"numAtRisk":5889}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pneumonia influenzal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pneumonia mycoplasmal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pneumonia viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pneumothorax traumatic","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Polyarteritis nodosa","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Polyhydramnios","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Portal hypertension","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Post infection glomerulonephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Post procedural discharge","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Post procedural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Post streptococcal glomerulonephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":5,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Post-traumatic headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Postoperative adhesion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Postoperative wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":4,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Postpartum haemorrhage","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Postpartum sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pre-eclampsia","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":4,"numAtRisk":6487},{"groupId":"EG005","numAffected":9,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Premature delivery","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":3,"numAtRisk":6487},{"groupId":"EG005","numAffected":8,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":2,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Premature labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":3,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Premature rupture of membranes","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Premature separation of placenta","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Preterm premature rupture of membranes","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pseudomembranous colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Psoriasis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Psychiatric symptom","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Psychogenic seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Puerperal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":4,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Pustule","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pyelocaliectasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":4,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":2,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pyoderma","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":5,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Quadriparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":12,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":3,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":2,"numAtRisk":5889}]},{"term":"Rectal polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Red blood cell sedimentation rate increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Refraction disorder","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Renal colic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Retinal haemorrhage","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Rheumatic fever","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Rheumatic heart disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Rickettsiosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":8,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":9,"numAtRisk":12961},{"groupId":"EG006","numAffected":3,"numAtRisk":2985},{"groupId":"EG007","numAffected":3,"numAtRisk":5990},{"groupId":"EG008","numAffected":3,"numAtRisk":2939},{"groupId":"EG009","numAffected":6,"numAtRisk":5889}]},{"term":"Ruptured cerebral aneurysm","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Ruptured ectopic pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"SARS-CoV-2 sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Salpingitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Scarlet fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Schwannoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Scrotal pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Self-destructive behaviour","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":4,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Septic phlebitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Serositis","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Serotonin syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Sexual abuse","organSystem":"Social circumstances","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":4,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Shunt malfunction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Simple partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Sinus node dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Sinus polyp","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Sinusitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Skin injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Skull fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Skull fractured base","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Small intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Snake bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Soft tissue injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Spinal cord injury thoracic","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Splenic rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Spondylitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Sports injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Stab wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Staphylococcal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Staphylococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Status migrainosus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Stillbirth","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Subarachnoid haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":4,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Subgaleal haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Substance use","organSystem":"Social circumstances","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Substance use disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Suicidal behaviour","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":5,"numAtRisk":6487},{"groupId":"EG005","numAffected":5,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":2,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Superinfection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Suspected COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":2,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Synovitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Syphilis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Systemic lupus erythematosus","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Systemic viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Tendon injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Tendon rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Tension headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Testicular injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Testicular torsion","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Thalassaemia alpha","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Threatened labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Thrombocytopenic purpura","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Thrombotic thrombocytopenic purpura","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Tibia fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":5,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":4,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Tinea capitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Tonsillar hypertrophy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":2,"numAtRisk":13033},{"groupId":"EG004","numAffected":3,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Tonsillitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":4,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":5,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Tooth fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Toxicity to various agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":2,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Traumatic delivery","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Traumatic haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Traumatic haemothorax","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Traumatic intracranial haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Traumatic liver injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Traumatic lung injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Type I hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Typhoid fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Ulcerated haemangioma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Ulna fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Umbilical cord prolapse","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Umbilical hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":2,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Unstable foetal lie","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Upper limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":2,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":6687},{"groupId":"EG001","numAffected":3,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":4,"numAtRisk":6487},{"groupId":"EG005","numAffected":9,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":2,"numAtRisk":5889}]},{"term":"Upper respiratory tract infection bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Ureterolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Urethral caruncle","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Urethritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Urinary bladder rupture","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":6687},{"groupId":"EG001","numAffected":9,"numAtRisk":13380},{"groupId":"EG002","numAffected":2,"numAtRisk":6519},{"groupId":"EG003","numAffected":4,"numAtRisk":13033},{"groupId":"EG004","numAffected":15,"numAtRisk":6487},{"groupId":"EG005","numAffected":20,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":3,"numAtRisk":5990},{"groupId":"EG008","numAffected":2,"numAtRisk":2939},{"groupId":"EG009","numAffected":3,"numAtRisk":5889}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":4,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":2,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Vaginal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Varicella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":1,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Vasculitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Venom poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Ventricular arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Victim of crime","organSystem":"Social circumstances","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Victim of sexual abuse","organSystem":"Social circumstances","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":1,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":6687},{"groupId":"EG001","numAffected":23,"numAtRisk":13380},{"groupId":"EG002","numAffected":4,"numAtRisk":6519},{"groupId":"EG003","numAffected":3,"numAtRisk":13033},{"groupId":"EG004","numAffected":17,"numAtRisk":6487},{"groupId":"EG005","numAffected":16,"numAtRisk":12961},{"groupId":"EG006","numAffected":3,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":5,"numAtRisk":2939},{"groupId":"EG009","numAffected":3,"numAtRisk":5889}]},{"term":"Viral myocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Viral pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Viral rash","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":4,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Vulval haematoma","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Vulvovaginal injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":1,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":1,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Wound dehiscence","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":1,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":1,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":3,"numAtRisk":12961},{"groupId":"EG006","numAffected":1,"numAtRisk":2985},{"groupId":"EG007","numAffected":1,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]},{"term":"Wrist fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6687},{"groupId":"EG001","numAffected":0,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":0,"numAtRisk":2985},{"groupId":"EG007","numAffected":0,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":1,"numAtRisk":5889}]}],"otherEvents":[{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":337,"numAtRisk":6687},{"groupId":"EG001","numAffected":736,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":82,"numAtRisk":2985},{"groupId":"EG007","numAffected":206,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":363,"numAtRisk":6687},{"groupId":"EG001","numAffected":1011,"numAtRisk":13380},{"groupId":"EG002","numAffected":0,"numAtRisk":6519},{"groupId":"EG003","numAffected":0,"numAtRisk":13033},{"groupId":"EG004","numAffected":0,"numAtRisk":6487},{"groupId":"EG005","numAffected":0,"numAtRisk":12961},{"groupId":"EG006","numAffected":113,"numAtRisk":2985},{"groupId":"EG007","numAffected":340,"numAtRisk":5990},{"groupId":"EG008","numAffected":0,"numAtRisk":2939},{"groupId":"EG009","numAffected":0,"numAtRisk":5889}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement."},"pointOfContact":{"title":"Study Director","organization":"Takeda","email":"TrialDisclosures@takeda.com","phone":"+1-877-825-3327"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-09-14","uploadDate":"2025-09-11T09:59","filename":"Prot_004.pdf","size":2184520},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-09-24","uploadDate":"2021-07-23T12:45","filename":"SAP_003.pdf","size":28383641}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Peru","Vietnam"]},"interventionBrowseModule":{"meshes":[{"id":"D053059","term":"Dengue Vaccines"}],"ancestors":[{"id":"D014765","term":"Viral Vaccines"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"}]}},"hasResults":true}